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miR-484 Functions as an Onco-miR in Triple Negative Breast Cancer 
Nashwa Kabil M.D. 
Supervisory Professor: Bulent Ozpolat M.D. Ph.D 
 
Abstract: 
Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer 
(BC), with a poor prognosis with currently used therapies, and thus represents an unmet 
therapeutic challenge.  Lack of molecular targets (i.e. ER, PR, HER2) and significant 
genetic heterogeneity are the major reasons contributing to early relapse and high 
mortality rates.  Numerous studies have indicated that microRNAs (miRs) have an 
important role in BC progression, invasion, angiogenesis, and metastasis.  We analyzed 
miRNA expression profiles of BC patient data bases and identified that miR-484 is highly 
upregulated in all subtypes of BC patients, with the highest expression in TNBC patients.  
miR-484 was found to be  associated with significantly shorter patient survival, while 
inhibition of miR-484 in TNBC cells led to significant reduction of cell proliferation, motility 
and invasion, and induced cell cycle arrest and apoptosis.  Furthermore, we found that 
miR-484 is inversely correlated with levels of HOXA5 in patients’ tumors and 
demonstrated that miR-484 directly binds to the 3-untranslated region (3-UTR) of 
HOXA5 mRNA to suppress its expression. Moreover, HOXA5 over-expression 
recapitulated the effects of miR-484 inhibition.  In vivo therapeutic targeting of miR-484 
by systemic administration of anti-miR-484 nanoparticles significantly induced HOXA5 
expression and suppressed tumor growth and progression in orthotopic xenograft mouse 
models of TNBC.  Thus, our findings provide new insights about the oncogenic role of 
miR-484 and suggest that miR-484 represents a novel therapeutic target in TNBC.   
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Breast Cancer Statistics 
It is estimated that about 1 out of 8 women in the U.S. (about 12.4%) will develop invasive 
breast cancer (BC) throughout their lifetime.  Over a quarter of a million new cases of 
invasive BC are expected to be diagnosed by the end of 2018 in women in the U.S, with 
an estimated 41,000 deaths (1).   Worldwide, BC still remains a global burden, with the 
latest reported statistics by the global cancer project (GLOBOCAN 2012), estimating 
more than 1.5 million newly diagnosed cases of BC, and over 500,000 deaths.  Despite 
the advancement in BC management, it still remains the most common cancer in women, 
accounting for more than a quarter of all cancer cases (2).   The incidence of BC is higher 
in developed countries (western world),  while relative mortality is greater in developing 
countries (2).  This discrepancy can be largely attributed to differences in socio-economic 
status, availability of early screening and detection programs, and access for treatment 
(2). 
The Heterogeneity of Breast Cancer 
BC is a highly heterogenous disease, composed of multiple subtypes, with each subtype 
displaying specific morphological features, which can account for differences in tumor 
behaviors, as well as therapeutic response to treatment (3).   Historically, BC has been 
classified according to the expression of three molecular markers: estrogen receptor 
(ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 
(HER2) (4).  These molecules also serve as druggable targets for specific therapies (5).  
BC tumors that lack ER, PR, and HER-2 receptors are classified as triple-negative breast 
cancer (TNBC); a highly aggressive and metastatic subtype of BC, with poor responses 
to targeted therapies (6, 7). Subsequent studies utilizing gene expression-profiling 
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revealed that BC is highly heterogeneous and subtyping was expanded beyond the 
original ER/PR/HER2 classification (4, 8, 9).  Other clinico-pathological variables such as, 
tumor size, tumor grade, and lymph node status, are also used to predict patient 
prognosis and management (10, 11).   
 
Gene expression profiling and intrinsic molecular subtypes 
 
In the era of the human genome project, the emergence of microarrays, and other gene 
expression profiling platforms has led to the development of an intrinsic subtyping system 
using multiple genes in order to classify BC (4, 8).  Perou and colleagues conducted the 
first study that classified the molecular subtypes of BC into the following 4 subtypes: 
estrogen receptor positive (ER+)/luminal-like, basal-like, receptor tyrosine kinase positive 
(HER2/neu+), and normal breast (4).  According to Perou and colleagues, most of the 
triple-negative breast cancers (TNBCs) were included in the basal-like subtype (4, 12).   
Subsequently, Sorlie and colleagues identified five major molecular types, that included 
luminal A, luminal B, HER2 over-expression, basal, and normal-like tumors (4, 8, 9).  Each 
of these subtypes harbors specific histopatholoical features that can affect clinical 
progression and treatment outcome (13-18).  Other gene signatures were introduced 
later, including the PAM50 classification which depends on the expression of hormone 
receptors, in addition to proliferation related genes, and genes exhibiting myoepithelial 
and basal features (19-21).  These markers were found to be clinically significant as 
having prognostic value and help in predicting therapeutic outcome (22).  
Luminal A tumors (ER+/PR+) are frequently low-grade tumors and respond well to ER 
targeted therapies such as tamoxifen and aromatase inhibitors (17, 23).  Luminal B 
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tumors (ER+ with or without HER2+ and Ki67 overexpression) tend to be more aggressive 
subtype that may respond to hormonal therapies, but are also frequently associated with 
recurrence and poorer response (22, 24, 25).  HER2+ tumors (ERBB2/HER2 amplified) 
while they are regarded as an aggressive subtype, are sensitive to anti-HER2 therapies 
such as monoclonal antibodies (eg. trastuzumab and pertuzumab) or the small-molecule 
kinase inhibitor lapatinib (25, 26).   
Basal tumors 
Basal tumors do not express ER, PR, or HER2R and display expression profiles similar 
to basal epithelial cells, as wells as normal breast myoepithelial cells (4).  They also have 
high expression of basal markers such as keratins 5, 6, 14, 17, and epidermal growth 
factor receptor (EGFR), and proliferation related genes (4, 27).  These tumors are more 
frequently associated with low BRCA1 expression (28) and TP53 mutations (8, 29).  Basal 
tumors, which account for 60% to 90% of triple negative tumors (13, 30), tend to follow 
an aggressive clinical course, with more likelihood to metastasize to distant organs, with 
the exception to bone, and lymph nodes (31).  Given their lack of expression of hormonal 
receptors, basal tumors are not sensitive to anti-hormonal targeted therapeutics, leaving 
conventional chemotherapies as their only therapeutic option (32). 
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Triple Negative Breast Cancer 
Characteristics & Risk Factors  
Approximately 15% to 20% of all diagnosed BC cases are TNBC.  These tumors share 
considerable molecular similarities with basal-like cancers  (up to 70% overlap).  
However, TNBC and basal subtypes are histo-pathologically and clinically distinct, and  
thus these two subtypes are mutually exclusive (33, 34).  TNBCs more prevalent in 
African-American or Hispanic women of younger age (<40 years) (4, 6, 35).  Other risk 
factors for TNBC include multiple and early pregnancies, as well as lack of breast feeding 
(36, 37).   At stage of presentation, TNBCs are mainly poorly differentiated invasive ductal 
carcinoma with a tendency to metastasize to the lung and brain (38, 39).  However, unlike 
other BC subtypes, the correlation between TNBC tumor size and lymph node status is 
not clearly defined (40-42).  TNBCs have the worse prognosis compared with other BC 
subtypes, with an estimated 5 year survival rate of 70% (3).  This survival rate is much 
lower for patients with advanced metastasis (~12 month survival) (43, 44).  
Molecular Heterogeneity of TNBC 
TNBCs are a highly heterogeneous subtype of BC that is composed of 6 molecular 
subtypes according to the study by Lehman and colleagues.  Each subtype displays 
distinct oncogenic drivers that can thus be utilized as potential molecular targets.  These 
subtypes include: basal-like (BL1 and BL2), immunomodulatory (IM), mesenchymal (M), 
mesenchymal stem–like (MSL), and luminal androgen receptor (LAR).  In their study, they 
also identified TNBC cell line models representing each subtype to be utilized in targeting 
specific oncogenic pathways identified in the gene expression analysis.  These 
subclasses were found to display distinct therapeutic responses that correlate with 
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pathologic complete response (pCR) rates following neoadjuvant chemotherapy (NAC) 
(45).  For example, BL1 and BL2 subtypes displayed higher expression of cell cycle and 
DNA damage proteins, and representative cell lines showed a favorable response to 
taxane-based therapies.  BL1 tumors show the most favorable pCR rates (52%) 
compared to other subtypes after NAC, whereas BL2 patients display the lowest pCR 
(46).  M and MSL subtypes showed higher expression of epithelial-mesenchymal 
markers, and growth factor pathways which responded well to a PI3K/mTOR inhibitors 
and an Abl/Src inhibitors (7).  Patients with MSL subtype displayed upregulation of 
transforming growth factor receptor III (TGFβ-III), a known driver of migration and invasion 
(47), and showed moderate pCR rates (between 20-30%) (46).  The LAR subtype 
includes patients characterized by androgen receptor (AR) signaling, with frequent 
display of positive PI3KCA activating mutations (48).  LAR subtype patients are less 
responsive to chemotherapy, with a pCR rate of around 10% (46), but display favorable 
response to anti-androgen treatments in combination with PI3K inhibitors (48).  Finally, 
the IM subclass display higher expression of immune response signaling proteins, and 
have a moderate pCR of around 30% (46). 
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Current Therapeutic Strategies for TNBC 
Currently, there are no approved targeted therapeutics available for TNBC, although there 
are a several drugs in pre-clinical and clinical trials that are being investigated (49, 50).  
Taxane based therapies (eg. docetaxel or paclitaxel), anthracyclines (eg. doxorubicin or 
epirubicin) and alkylating agents (eg. Cyclophosphamide) are still considered the gold 
standard of therapy for TNBC (49).   Given that approximately 15-20% of TNBCs harbor 
BRCA 1/2 mutations (51), platinum based therapies that affect the DNA repair mechanism 
have been proven to be effective in TNBC patients (50, 52).  Also other therapeutic 
options include poly ADP ribose polymerase inhibitors (PARP inhibitors), Src family 
kinase inhibitors, EGFR inhibitors, as well as anti-androgens (50).  A small percentage of 
TNBC patients, particularly  mesenchymal and luminal androgen receptor (LAR) subtypes 
have also been shown to benefit from PI3K/AKT/mTOR inhibitors (50).  Another emerging 
concept in TNBC management is the use of immune checkpoint inhibitors, targeting either 
the programmed death (PD)-1 receptor or its ligand PD-L1, in combination with either 
cytotoxic chemotherapy or radiotherapy (53, 54). 
Drug Resistance in TNBC 
TNBC management remains an extensive clinical challenge due to its aggressive course 
and poor therapeutic outcome (6, 35, 55, 56), compared with other BC subtypes (57-59).  
Substantial tumor heterogeneity is one of the major reasons for the development of drug 
resistance, resulting in the selective survival of residual tumor cells that can repopulate 
the tumor and result in relapse (60).  Other evidence suggests, that some cytotoxic agents 
can promote epithelial-mesenchymal-transition (EMT) and or enrich the tumor initiating 
cell population to promote metastasis (61).   
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Due to the lack of effective targeted therapeutics, new interest has emerged in identifying 
new molecular targets and development of therapeutic strategies against them in order 
to improve TNBC patient survival and prognosis.  In recent years, numerous publications 
have highlighted the critical role of  miRNAs in cancer (62).  Extensive research over the 
years has shown that micro RNAs (miRNAs) are implicated in all stages of BC (63, 64), 
which has rendered them as valuable diagnostic and prognostic markers (65).  Recently, 
there has been a growing interest in the use of miRNA based therapeutic strategies in BC 
(66). 
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Role of miRNA in the Pathogenesis of Breast Cancer  
The initial discovery of miRNAs was in early 1990s by Ambros and Lee that found that 
short non-coding region of lin-4 negatively regulates the expression of lin-14 during larval 
development of C. elegans (67).  Later that year, lin-4 was shown to bind to the lin-14 3’ 
untranslated region (3’-UTR) that harbors multiple conserved sequences complementary 
to lin-4 (68).  As of 2001, these short non-coding RNAs were classified as a new set of 
genes called micro RNAs (miRNAs) (69-71). 
miRNA Biogenesis & Mechanism of Action  
miRNA genes reside in either intergenic, or intragenic (intronic or in exonic) regions within 
the genome. They can be transcribed as a single transcript from its own promoter or 
several miRNAs can share a promoter and be transcribed as a long polycistronic primary 
transcript (72-74).   
miRNA are primarily transcribed by RNA polymerase II into a long primary transcript 
called pri-miRNA which can have a nucleotide length up to 1kb.  This pri-miRNA is 
5’capped and 3’ poly-adenylated (72, 75), and then converted into a hair pin structure 
around 70-80 nct. called pre-miRNA by ribonucleases III enzyme DROSHA and RNA-
binding protein Digeorge Critical Region 8 (DGCR8), also known as Pasha (75).  
Subsequently this pre-miRNA is then transported form the nucleus into the cytoplasm by 
Exportin 5 (XPO5), to undergo further processing by DICER (RNAse III endonuclease 
enzyme) into a double stranded miRNA, which is around 18-25 nct in length (76).  This 
double stranded structure is then unwound and single strands, composed of a guide 
strand and a passenger strand, are then loaded on to the RNA-Induced Silencing 
Complex (RISC) to its target mRNA (77) (Figure 1). 
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Figure 1: Gene silencing mechanisms of miRNAs 
This figure is reused with permission and was originally published by I. Fernandez-
Piñeiro, I. Badiola, and A. Sanchez in Biotechnology Advances, 2017. 
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miRNAs mainly act by regulating gene expression at the post-transcriptional level  
depending on the degree of sequence complementarity between the miRNA and its target 
mRNA. They can either lead to mRNA degradation, in the case of perfect 
complementarity; or translational inhibition, in the case of imperfect complementarity (78). 
The binding of miRNAs and their target mRNAs mainly occurs by interaction between the 
3’-UTR of the mRNA with the miRNA seed sequence (∼6–8 nt), which is located near 
their 5’ end, and was found to be  highly conserved (79).  The 3’-UTR of a single mRNA 
can bind to multiple miRNAs and any single miRNA can bind to hundreds of targets.  
Thus, miRNAs have the ability to regulate many signaling pathways simultaneously (80, 
81).  The binding between miRNAs and their target mRNAs can be computationally 
predicted using a number of highly accurate predictive algorithms, which can then be 
experimentally verified (82, 83).   Currently, there over 2600 mature human miRNAs 
according to the miRbase database humans [http://www.mirbase.org/]. 
Although miRNAs mainly act by binding to the 3’-UTR of their target mRNAs, several 
other mechanisms have also been proposed as means of their actions.  For example, 
miRNAs can by bind to the 5’-UTR regions to increase mRNA translation (84, 85), as in 
the case of miR-10b, which was shown to bind the 5’-UTR of ribosomal protein mRNA 
and increase their translation (85).  Other miRNAs, such as let-7 and miR-363, were found 
to increase mRNA expression by recruitment of specific micro-RNPs (eg. Argonaute 2 
(AGO) and fragile X mental retardation-related protein 1 (FXR1), to the AU rich regions 
in the 3’-UTR of their target mRNA (84).  Some studies have also suggested that miRNAs 
can be translocated to the nucleus to activate the promotor region of their target genes 
and increase transcription (86).  For instance, miR-551b-3p was found to recruit RNA 
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polymerase II and the transcription factor Twist related protein 1 (TWIST1) to the signal 
transducer and activator of transcription (STAT3) promoter region, to activate its 
transcription (86).  Additionally, some miRNAs can localize to  different subcellular 
compartments, as in the case of miR-29b, which has a specific hexanucleotide terminal 
sequence that directs its translocation to the nucleus (87).  Also a few miRNAs can bind 
to RNA-binding proteins and thus inhibit their binding with their target (88).  Thus, the 
mechanism of miRNA-mediated regulation of gene expression is a mutli-facted subject 
that requires further exploration.   
 
Role of miRNA in Cancer 
The role of miRNA in cancer was first described in 2002, where it was found that the 
chromosomal region 13q14, which is frequently deleted in chronic lymphocytic leukemia 
(CLL) patients (89, 90), harbors a chromosomal translocation at t(2:13) at a fragile site 
resulting in the deletion of the miR-15a/16-1 cluster (91), suggesting their potential role 
as tumor suppressors.  The following year in a follow up study, miRNAs were mapped in 
chromosomal fragile sites, regions of loss of heterozygosity, or regions of amplifications 
(92).   Furthermore, in 2005, another study reported that the miR 17~92 cluster, induced 
by c-MYC, enhances lymphoma in mouse models of B-CLL, suggesting its possible role 
as an oncogenic miRNA (93).  These discoveries paved the way for a new era of 
biomedical research in deciphering the role of miRNAs in tumorigenesis, resulting in more 
than 30,000 publications recorded on PUB MED to date. 
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Mechanisms Altering miRNA Expression in Cancer   
The aberrant expression of miRNAs in cancer can be attributed to many factors discussed 
below (62).  
Genetic Regulation:  miRNAs can reside within the chromosomal regions that are 
proximal to fragile sites, or in regions of loss of heterozygosity, deletions, amplifications, 
or translocations. Chromosomal regions that harbor miRNAs involved in negatively 
regulating known tumor suppressors (oncogenic miRNAs), may be amplified, resulting in 
increased expression of these oncogenic miRNAs and subsequent reduction in the 
expression of their tumor suppressor genes (94).  On the other hand, miRNAs that inhibit 
oncogenes (tumor suppressor miRNAs) are located at chromosomal fragile sites, where 
deletion or mutations can decrease their levels, resulting in overexpression of their target 
oncogenes (94).  Such is the case for miR15a/16-1, which were found to be 
deleted/translocated in the majority of CLL patients (91), and were later revealed to target 
the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) in CLL (95). 
Epigenetic Regulation:  The presence of DNA-binding factors can affect the promoter 
regions of miRNA genes. This can result in the downregulation of miRNA genes by hyper 
methylation or histone deacetylation of the promoter regions (96).  For example, the miR-
9-1 gene in BC is downregulated due to hyer-methylation of its promoter regions (97).  
Other means of epigenetic regulation include histone deacetylation and tri-methylation, 
as in the case of miR-29 in B-cell lymphoma (98).  On the other hand, histone acetylation 
can lead to the activation of miRNA genes, such as that of miR-224 in hepatocellular 
carcinoma (99).  Other miRNAs can be activated by transcription factors acting at their 
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promoter region.  For example, the tumor suppressor p53 was found to bind and activate 
the promoter regions of the miR-34a (100). 
Regulation of miRNA Biogenesis/Processing:  miRNAs expression levels can also be 
regulated by factors that affect their biogenesis or processing at multiple levels (101).  For 
example,  miRNA biogenesis proteins such as  DROSHA, DICER, DGCR8, TRBP, XPO5 
and AGO can be affected by genetic mutations, post-translational modifications, or 
binding to regulatory proteins, which can ultimately affect  miRNA expression levels (102).  
Additionally, single nucleotide polymorphisms (SNPs)  in a miRNA gene may alter miRNA 
processing efficiency by changing its stem–loop structure (101). 
Given that one miRNA can have up to several hundred mRNA targets, aberrantly 
expressed miRNAs in cancer may affect multiple transcripts and hence significantly 
impact numerous cancer signaling pathways (103).  For example, factors that lead to 
increased expression of miRNAs that are frequently over-expressed in cancer would lead 
to enhanced silencing of tumor suppressor genes.  Consequently, this may promote 
tumor formation by increasing cell proliferation, invasiveness, angiogenesis, or 
suppressing apoptosis.  On the other hand, under expression of tumor suppressor 
miRNAs in cancers could also promote tumorigenesis through upregulation of their 
oncogenic target mRNAs (104) (Figure 2). 
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Figure 2: miRNAs can function as tumor suppressors or oncogenes 
This figure is reused with permission and was originally published by Aurora Esquela-
Kerscher, Frank J. Slack in Nature Reviews Cancer, 2006. 
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MicroRNAs in Breast Cancer  
Several platforms have been developed to profile the global expression of miRNAs in 
normal or diseased tissues.  In the context of cancer, these profiling studies have been 
used to aid in tumor classification and the assessment of diagnosis and prognosis (62).  
Iorio and colleagues, in 2005, were the first to describe a specific miRNA signature pattern 
that were differentially expressed  in normal vs. BC tissue, and was correlated with tumor 
grade, disease stage, vascular invasion, proliferation index, and hormone receptor 
expression (105).   Subsequently, several studies revealed that aberrantly expressed 
miRNAs are able to regulate many process in breast carcinogenesis, thereby acting as 
either oncogenic or tumor suppressor miRNAs (106).   In BC, miRNAs have been shown 
to regulate many processes such as cell cycle progression, apoptosis, angiogenesis, 
epithelial-mesenchymal transition, metastasis, and drug resistance (64).  
 
Oncogenic miRNAs in Breast Cancer    
Micro RNAs have been demonstrated to be key modulators in controlling the primary 
tumor growth, as well as in promoting the metastatic process, and modulating the 
interaction of the tumor with its microenvironment (107, 108).  Some of the well described 
examples of oncogenic miRNAs in BC are discussed below and are listed in Table 1.  
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miR-21: 
Among the differentially expressed miRNAs that were shown to be upregulated in BC 
patients and speculated to be oncogenic was miR-21, which was later one of the most 
extensively researched miRNAs with oncogenic properties.  Some of its oncogenic 
properties to promote BC cell survival and proliferation may be attributed to targeting 
tumor suppressors such as phosphatase and tensin homolog (PTEN) (109), programmed 
cell death 4 (PDCD4) (110) and tropomyosin 1 (TPM1) (111).   Additionally, the clinical 
significance of miR-21 in BC was demonstrated by studies that found it to be associated 
with advanced clinical staging, lymph node status, and worse prognosis in BC patients 
(112, 113). 
miR-10b:  
miR-10b was shown to be an oncogenic driver of BC, by promoting migration and invasion 
in metastatic BC cells.  Moreover, it was also shown to initiate invasion and metastasis in 
non-metastatic breast cells.  miR-10b expression is enhanced by the transcription factor 
TWIST1, which binds to its promoter region.  miR-10b acts by binding and inhibiting the 
expression of HOXD10, which then enhances the expression of the pro-metastatic gene, 
Ras homolog gene family member C (RHOC) protein  (114).  miR-10b was also shown 
to be a miRNA of clinical significance as it was found to be positively correlated with BC 
staging, histological grading, and lymph node metastasis (115).  Additionally, miR-10b 
was shown to target E-cadherin in metastatic BC cells to promote cell invasion (116). 
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miR-155: 
miR-155 is another miRNA that was found to be frequently up-regulated in breast tumor 
tissue and was found to be associated with clinicopathologic markers, BC subtype, and 
poor survival rates (105, 117, 118) . miR-155 was found to act via targeting and 
downregulating the expression forkhead box O3 (FOXO3a) to enhance tumor cell 
sensitivity to chemotherapy and mediate apoptosis  (119).  Other studies suggested that 
miR-155 promotes BC oncogenesis by targeting suppressor of cytokine signaling 1 
(SOCS1), leading to the activation of the JAK/STAT3 pathway.  In that study, miR-155 
expression was found to be induced by inflammatory cytokines such as IL-6 and INF-γ, 
suggesting its possible relationship to inflammation in cancer (120).  Additionally, miR-
155 was shown to target caspase-3 in activated macrophages to promote their survival 
in the inflammatory response (121). 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
19 
 
Table1: Oncogenic miRNAs in Breast Cancer  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oncogenic 
miRNA 
Target 
Cancer Related 
Events 
References 
miR-21 
TPM1,  
PDCD4,  
TIMP3,  
PTEN 
 
Cell proliferation,  
Apoptosis,  
Invasion 
(110, 111, 
122, 123) 
miR-155 
FOXO3a, 
SOCS1, 
caspase-3, 
TP53INP1 
Cell proliferation, 
Apoptosis, Cell 
cycle progression 
(119-121, 
124) 
miR-10-b HOXD10, Tiam1 
Invasion, 
Migration, 
Metastasis 
(125, 126) 
miR-9 E-cadherin 
Cell motility, 
Invasion, 
Angiogenesis, 
Metastasis 
(127) 
miR-27a 
HOXO1, 
ZBTB10 
Cell proliferation, 
Cell cycle 
progression, 
Angiogenesis, 
Metastasis 
(128-130) 
miR-181a Bim 
EMT, Migration, 
Invasion, 
Metastasis 
(131) 
miR-182 
RECK, MIM, 
FOXO1 
Cell proliferation, 
Invasion 
(129, 132) 
miR-221/222 
TRPS1, 
ADIPOR1, 
p27Kip1 
EMT (133-135) 
miR-373/520c CD44 
Migration, 
Invasion, 
Metastasis 
(136) 
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Tumor Suppressor miRNAs in Breast Cancer 
Let-7 family: 
One of the well characterized examples of tumors suppressor miRNAs in BC is the let-7 
family.  Several groups have reported that the let-7 family are differentially expressed in 
BC, as well as in other tumors (137-139).   Let-7, tumor suppressor microRNA was 
originally discovered in C. elegans, where it was found to regulate cell differentiation and 
cell cycle (140).  This family has been shown to act as tumor suppressor miRNAs by 
targeting critical oncogenes such as RAS, high-mobility group AT-hook 2 (HMGA2), c-
Myc, and caspase-3 (141-144), as well as several genes involved in  stem cell 
maintenance (145).   
miR-34 family: 
Another well characterized tumor suppressor miRNA family in BC is the miR-34 family.   
The miR-34 family is composed of 3 members: miR-34a, which is encoded by its own 
gene from chromosome 1p36, and miR-34b/c which are co-transcribed from a shared 
locus on chromosome 11q23 (146).  miR-34a is the most extensively studied member in 
cancer and was found to inhibit many different oncogenic processes relating to tumor cell 
differentiation, proliferation, migration, and invasion by targeting BCL-2 and SIRIT1 (147, 
148); and induce apoptosis and cell cycle arrest (100).   Previous studies have shown 
that miR-34a js transcriptionally activated by tumor suppressor p53, and thereby 
contributes to p53 mediated downstream effects on cell cycle arrest and induction of 
apoptosis, by targeting c-MYC, CDK6, and c-MET (146).  Other studies have also shown 
that miR-34a targets NOTCH, epithelial-mesenchymal transition (EMT), and transforming 
growth factor beta (TGF-β) signaling pathways, as well as elongation factor 2 kinase 
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(EF2-K) and forkhead box protein M1 (FOXM1) axis, WNT/β-Catenin pathways (146, 149, 
150). 
 
miR-200 family: 
There are five members of the miR-200 family, which are organized into two clusters.  
Cluster 1 is composed of miR-200a, miR-200b, and miR-429, located on chromosome1, 
while, cluster 2 is composed of  miR-200c and miR-141 (miR-200c/141) located on 
chromosome 12 (151).  Previous studies have shown the miR-200 family is involved in 
regulating EMT by zinc finger E-box-binding homeobox 1 (ZEB1) and ZEB2, which are 
transcriptional repressors of E-cadherin, and thereby maintaining an epithelial like state 
(152-154).  On the other hand, other studies have shown the existence of a reciprocal 
feedback loop where ZEB1 and ZEB2 also act by repressing miR-200 transcription (155, 
156).      
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Table 2: Tumor Suppressor miRNAs in Breast Cancer  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Tumor 
Suppressor 
miRNA 
Targets 
Cancer Related 
Events 
References 
Let-7 family H-Ras, HMGA2, 
PAK1, DIAPH2 
Stemness, Cell 
motility, Migration, 
Invasion 
(157-159) 
miR-34 family 
BCL-2, SIRIT1 
c-MYC, CDK6, 
c-MET, 
NOTCH1, EF-
2K, FOXM1 
Cell proliferation, 
Migration, 
Invasion, EMT, 
Cell cycle 
progression, 
Apoptosis 
(147, 148) 
(146, 160, 
161) 
miR-200 family 
ZEB1, ZEB2, 
HER3, Sec23a, 
SIRT1 
EMT, Stemness, 
Metastasis 
(162-165) 
miR-145 
IRS-1, ER-α, 
RTKN, MUC1, 
OCT4, N-Ras, 
VEGF-A 
Cell proliferation, 
EMT, Invasion, 
Metastasis, 
Angiogenesis 
(166-171) 
miR-205 ZEB1, ZEB2, 
HER3, VEGF-A 
EMT, Cell 
proliferation, 
Invasion, 
Stemness 
(172-175) 
(176) 
miR-30 family 
MTDH, FOXD1, 
AVEN, VIM, 
Eya2, Vimentin, 
KRAS, MAPK, 
TWFI 
Cell proliferation, 
Cell cycle 
progression, 
Apoptosis, 
Invasion, Chemo- 
sensitivity 
(177-181) 
miR-335 
SOX4, tenascin 
C, ER-α, IGF1, 
RSP1, ID4 
Cell proliferation, 
Apoptosis, 
Metastasis 
(182-184) 
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miRNAs as Diagnostic & Prognostic Markers in Breast Cancer  
Recent evidence has suggested that circulating miRNAs are present in several body 
fluids including blood, serum, saliva, urine, and breast milk (185-187).  Circulating 
miRNAs are either free or packaged into vesicles such as exosomes, apoptotic bodies, 
or incorporated with high density lipoproteins, or AGO proteins (188).  Thus circulating 
miRNAs are stable, easily detected by non-invasive measures, making them ideal 
biomarkers for early cancer detection and predictors of therapeutic outcome (65).   
 
Studies have indicated that miRNAs may be valuable diagnostic markers for early 
detection of BC.  One of the most extensively studied miRNAs in cancer is miR-21, which 
has been shown in numerous studies to be a useful diagnostic biomarker for BC, as it is 
significantly overexpressed in either plasma/serum or tissue samples of BC patients 
compared to normal healthy volunteers (189-192).   Furthermore, miR-21 proved to be a 
highly reliable biomarker, displaying higher sensitivity than other well characterized 
markers, such as clinical cancer antigen 15-3 (CA153) and carcinoembryonic antigen 
(CEA) in BC diagnosis (191).  Other extensively studied oncogenic miRNAs for BC 
diagnosis include miR-155 (193-195) and miR-18a (196, 197). 
 
miRNAs could also serve as prognostic tools in BC whereby their expression can predict 
patient survival and treatment outcome.  For example, high miR-21 expression levels 
were shown to be associated with reduced disease-free survival (DFS) and overall 
survival (OS), as well as clinical staging and lymph node metastasis in BC patients (112, 
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198, 199).  Furthermore, miR-21 was also shown to have prognostic value as it was 
demonstrated to be highly expressed in the bone marrow of BC patients (200). 
 
miRNAs as Markers for Therapeutic Response 
miRNAs could also be predictive of therapeutic outcome, whereby their expression levels 
could indicate either sensitivity or resistance to treatment.  For instance, high expression 
of miR-210 in tissues has been associated with poor patient survival and prognosis in 
ER+ tamoxifen-treated BC patients (201).  Similarly, high levels of miR-210 was also 
found to be correlated with trastuzumab resistance in HER2+ breast tumors (202).  
 
miRNAs as a Novel Class of Targeted Therapeutics 
Give the critical role of miRNAs in carcinogenesis, and their ability to simultaneously 
regulate many targets/pathways, a growing interest in recent years has been in utilizing 
miRNA based therapies as a therapeutic modality in cancer (203).  This can be achieved 
by either restoring tumor suppressive miRNAs (miRNA mimetics) or by inhibition of 
oncogenic miRNAs (miRNA inhibitors) (203). 
Restoring Tumor Suppressor miRNAs in Breast Cancer 
Restoring the expression and function of tumor suppressor miRNAs can be achieved by  
miRNA mimics which are synthetic oligonucleotides that can also be chemically modified 
(2′-O′methoxy) to increase their stability (204).  By replacing the lost or suppressed tumor 
suppressor miRNAs, these synthetic molecules can be loaded into the RISC complex to 
achieve downstream target inhibition (203).  Several studies have validated the efficiency 
of miRNA replacement therapies in many in vitro and in vivo models of cancer (203), 
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including BC  (205, 206).  For example replacement of the tumor suppressor Let-7 miRNA 
by lenti-viral system lead to decrease cellular proliferation, self-renewal, and metastasis 
of BC cells (207).  Another example is the replacement of miR-145 and miR-205 , which 
were found to restore functional BRCA1 gene in BC (208).  Furthermore, down-regulated 
tumor suppressor miRNAs such as miR-205, miR-126, miR-335, and miR-451 can be 
restored through miRNA replacement therapy (157, 209, 210). 
 
Targeting oncogenic miRNAs in Breast Cancer 
miRNA inhibitors are single stranded oligonucleotides that are complementary to  
endogenous miRNAs and have the ability to bind/sequester miRNAs and thereby prevent 
their processing by the RISC complex.  Some examples of miRNA inhibitors include: anti-
miRNAs (AMOs), locked nucleic acids (LNAs), antagomirs, and miRNA sponges (203). 
 
Anti-miRNA oligonucleotides (AMOs) are single-stranded, anti-sense oligonucleotides, 
that can bind to their selected miRNA by Watson Crick interaction, and thus prevent the 
miRNA from binding to its target (211).  AMOs have shown to be successful in 
suppressing miR-21 levels in BC cells both in vitro and in vivo.  For instance, the use of 
anti-miR-21 oligonucleotides were found to suppress both MCF-7 cell growth in vitro and 
tumor growth in vivo in xenograft mouse models.  Furthermore, the effect of miR-21 
inhibition in decreasing cell growth was also associated with an increase in apoptosis, in 
part by downregulation of the anti-apoptotic protein Bcl-2 (212). 
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AntagomiRs are chemically modified synthetic oligonucleotides that are complementary 
to miRNAs and can effectively compete with miRNAs for their target mRNAs with a 
stronger binding affinity (213).   AntagomiRs are modified by the addition of 2’-O-methoxy 
group on the ribose residues, partial replacement of phosphodiester bonds to 
phosphorothioate, and the addition of a cholesterol motif at 3′ end (213).  The 2′-O-
methoxy and phosphorothioate modifications help improve their bio-stability, whereas the 
cholesterol conjugation increases their cell distribution and permeation (214).  It has been 
demonstrated that antagomiR-21 can reduce cell proliferation and lead to induction of 
apoptosis in BC cells (212, 215).  Additionally, miR-21 antagomiRs were found to 
enhance the response to trastuzumab in resistant BC cells by upregulating PTEN (216). 
 
Locked nucleic acids (LNAs) are modified anti-sense oligonucleotides where the ribose 
moiety is locked in a C3’-endo conformation by an extra methylene bridge (217).  LNAs 
against miR-10b were found to be effective in inhibiting BC metastasis (218).  LNAs 
packaged in nano-liposomes were also found to prevent lymph node metastasis in 
orthotopic MDA-MB-231 tumor models (219).  Additionally, the use of LNA miR-21 
successfully reduced miR-21 expression levels as well as proliferation of BC cells (215). 
 
A miRNA sponge is a construct that encodes a mRNA containing multiple complementary 
binding sites in its 3′-UTR for the miRNA of interest (220).  Sponges can bind from 2-7 
specific seed sequences of the miRNAs of interest, and have the ability to bind to miRNAs 
from the same family (221).  Previous studies have shown that miR-9 sponges results in 
more than 50% reduction of miR-9 activity in 4T1 mammary tumor cells (127).  In addition, 
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miR-10b sponges effectively reduced cell growth, migration, and invasion in MDA-MB-
231 and MCF-7 BC cell lines, along with upregulating the expression of the miR-10b 
target HOXD10 (222) .  
 
Current Challenges in microRNA Delivery  
 
Despite the recent advances in the field of miRNA-based therapies, there are still many 
challenges to overcome in order to ensure safe and effective miRNA delivery in vivo.  
These obstacles include enzymatic degradation by nucleases, rapid renal clearance, as 
well the development of immune toxicities, and off-target effects (223, 224).  Thus, the 
use of miRNA modulators is limited due to their poor bioavailability, stability, and tissue 
permeability (223).   Therefore, several miRNA delivery systems have been engineered 
using viral or non-viral vectors in order to overcome these hurdles (225).  Although viral 
based vectors; made of either lentiviruses, adenoviruses, or adeno-associated viruses; 
have been shown to efficiently deliver miRNA modulators in vivo; their use is limited by 
their immunogenic effects (226).   Hence, the use of non-viral vectors may offer a safer, 
less toxic alternative (227).  One increasingly popular approach for miRNA delivery is the 
use of nano-carriers which are biocompatible and biodegradable carriers, that are highly 
versatile with the ability to modify their size and surface in order to enhance tumor-specific 
delivery (227).  Nano-carriers (1-1000nm) can be formed of inorganic materials such as 
gold or silica; or organic materials such as polymers or lipids; (228, 229) and offer the 
advantage of increased payload stability, and bioavailability, as well as selective 
accumulation at the tumor site due to the enhanced permeability and retention effect (228, 
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230).  Additionally, nano-carriers can be modified to express specific ligands for receptors 
on tumor cells (231). 
 
 
 
 
 
 
Figure 3: miRNA mechanism and modulation. Canonical biogenesis and 
processing of miRNAs and mechanism of RNAi-regulated gene silencing. 
 
This Figure is reused under the terms of the CC-BY-NC-ND license agreement 
(http://creativecommons.org/licenses/by-nc-nd/4.0/), and originally published by Maitri Y. 
Shah, Alessandra Ferrajoli, Anil K. Sood, Gabriel Lopez-Berestein, George A. Calin in 
EBio Medicine, 2016. doi:10.1016/j.ebiom.2016.09.017. 
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First miRNA-Based Clinical Trials 
Due to the great promise in utilizing miRNAs as therapeutic agents, there are now several 
ongoing clinical trials on miRNA based therapies in many cancers.  For example, the 
locked nucleic acid (LNA) against miR-122 Miravirsen (SPC3649), developed as 
treatment of hepatitis C virus (HCV), was found to safe and well tolerated in phase I 
clinical trial, and effective in Phase II trials, with a significant reduction in HCV RNA levels 
(232).    
 Another noteworthy example is the replacement therapy of the tumor suppressor miR-
34a by a liposomal mimetic (MRX34), which was evaluated in the first-in-human, phase I 
study, in patients with advanced solid tumors, including hepatocellular carcinoma, 
melanoma, and renal cell carcinoma (233).  However, this clinical trial was halted by 
miRNA Therapeutics due to multiple immune-related severe adverse effects that were 
observed (http://www.businesswire.com).  Therefore, dose optimization for miRNA based 
strategies is highly warranted in order to prevent potential adverse events. 
With the great promise that miRNA based therapies hold, there are still some obstacles 
that need to be overcome such as improving their safety, modes of delivery, and their 
therapeutic efficacy before their translation from the bench to the clinic.  However, a 
deeper understanding of the biological role of miRNAs could pave the way for a new era 
in personalized medicine. 
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Hypothesis & Aims: 
TNBCs represent a significant clinical challenge that is largely attributed to lack of 
effective targeted therapeutics, significant tumor heterogeneity, and poor response to 
conventional chemotherapies (6).  Therefore, better understanding of the biology of the 
disease and identification of novel molecular targets is crucial for the development of 
highly effective therapies to eradicate TNBC and improve patient survival.  Given the role 
of miRNAs in initiation, progression, metastasis, and drug resistance in various human 
cancers including BC, identification of clinically significant miRNAs that are involved in 
TNBC growth and progression is critical for better understanding of the complex biology 
of this cancer and for development of miRNA based strategies (106, 225).  Recent studies 
have shown that miRNA 484 was among seven miRNAs that were correlated with OS 
amongst various clinical and molecular subtypes of invasive ductal carcinoma patients 
(234).  Furthermore, miR-484 was also found to be significantly highly expressed in serum 
of early BC patients compared to healthy volunteers, suggesting that it may serve as an 
early diagnostic biomarker (235).  However, the role and mechanism of action of miR-484 
in TNBC has not been previously elucidated.  In light of this, we embarked on identifying 
clinically significant miRNAs using the The Cancer Genome (TCGA) database, and we 
identified miR-484, which we found to be clinically and prognostically significant and 
correlated with poor overall survival (OS) in BC (Fig. 4), supporting the previous findings.  
We further analyzed miR-484 expression profiles in all clinical BC subtypes including, 
ER+, ER-, HER2+, and TNBC, which we found to have the highest expression compared 
with normal breast tissues (Fig. 5).  Additionally, we found that miR-484 expression is 
significantly higher in basal subtype of BC compared to non-basal subtype and matched 
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normal breast tissues (Fig. 6).  Furthermore, we screened a panel of TNBC cells lines for 
basal miR-484 expression, and found that miR-484 was upregulated in all of our TNBC 
panel (2-10 folds) compared to normal mammary epithelial cells (MCF-10A) (Fig. 7).  . 
Overall Hypothesis: 
Thus, based on our preliminary data, as well as the recent findings, our overall hypothesis 
is that miR-484 acts as onco-miR to promote tumor growth & progression in TNBC.    
We tested this hypothesis with the following specific aims: 
Aim 1: Determine the functional role of miR-484 in TNBC cells in vitro. 
Aim 2: Determine the mechanism of action of miR-484 in TNBC cells. 
Aim 3: Determine the role of miR-484 in TNBC tumorigenesis in orthotopic TNBC mouse     
models. 
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Figure 4: High miR-484 expression is associated with shorter overall survival in 
breast cancer patients. Kaplan-Meier Survival curves analysis showing high miR-484 
expression is associated with shorter overall survival rate in BC patients compared with patients 
with low miR-484 expression (n=602) (p≤0.001).   
 
Low miR-484 
High miR-484 
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Figure 5: miR-484 expression is significantly higher in TNBC subtypes compared 
to non-TNBC subtypes and normal tissues. The number of patients is listed at the bottom 
of the graph (p≤0.001).  
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Figure 6: miR-484 expression is significantly higher in basal subtype of BC 
compared to non-basal subtypes. The number of patients is listed at the bottom of the graph 
(p≤0.001). 
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Figure 7: miR-484 levels are upregulated in TNBC cells.  Expression levels of miR-484 
in TNBC cell lines and normal breast epithelial MCF-10A cells by qRT-PCR.  Data was normalized 
to the expression of U6 as an endogenous control and represent means ± SDs of three 
independent experiments.
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Cell Lines and Culture conditions 
TNBC cell lines (MDA-MB-231, MDA-MB-436, MDA-MB-453, MDA-MB-468, MDA-MB-
361, BT-549, BT-20, BT-483, HCC-1937, and SUM-149) and human mammary epithelial 
cell lines (MCF-10A, HMEC) and) were purchased from the American Type Culture 
Collection (Manassas, VA).  TNBC cells were cultured in Dulbecco's modified Eagle's 
medium (DMEM/F12), with the exception of HCC-1937, which was cultured in RPMI1640, 
and all media were supplemented with fetal bovine serum (FBS 10%) and a 
penicillin/streptomycin (100-U/ml) (Sigma).  MCF-10A cells were cultured in DMEM/F12 
media with the addition of horse serum (5%), insulin, hydrocortisone, epidermal growth 
factor, and cholera toxin.  Cultured cells were kept in a water-saturated incubator (95% 
air–5% CO2) at a temperature of 37°C. 
The Cancer Genome Atlas (TCGA) and Bioinformatics Analysis 
Statistical analyses were performed in R (version 3.4.1) (http:///www.r-project.org/) and 
the statistical significance was defined as a p-value less 0.05.  We downloaded patient 
clinical information for the TCGA patients with breast invasive carcinoma from cBioPortal 
(http://www.cbioportal.org/).  For the miRNA-Seq data, we derived the 
‘reads_per_million_miRNA_mapped’ values for the mature form hsa-miR-484 
(MIMAT0002174) from the “Isoform Expression Quantification” files from Genomic Data 
Commons Data Portal (https://portal.gdc.cancer.gov/).  The log2-transformation was 
applied to the data.  We analyzed total of 914 invasive BC cases with miRNA data and 
clinical information available.  For 93 cases matched, normal solid tissue was available.   
To determine the expression difference for miR-484 among normal and tumor tissue of 
different subtypes, we first employed a Shapiro-Wilk test and verified that the data does 
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not follow a normal distribution.  The Kruskal-Wallis non-parametric test was applied to 
determine the relationship between miRNA expression and tissue type. Data is 
represented as box and-whisker plots (Box plot represents first (lower bound) and third 
(upper bound) quartiles, whiskers represent 1.5 times the interquartile range).   Univariate 
Cox proportional hazards model was fitted to evaluate the association between OS and 
covariates including miR-484 expression levels (dichotomized at the tertiles to create 
groups that are “high” or “low”) and available clinical variables (age at diagnosis, stage).   
Stage, age, and miR-484 were statistically significant factors in the univariate Cox 
proportional hazards models, and were included in the final multivariable analysis of OS.  
miR-484 was an independent factor (HR= 2.02, CI(95%)=(1.23, 3.31), Wald test p-value= 
0.005).  In order to visualize the survival difference the Kaplan-Meier plots were generated 
for “low” (first tertile) and “high” (last tertile) miR-484 groups.  We applied a Spearman's 
rank-order correlation test to measure the strength of the association between HOXA5 
expression and miR-484 expression.  We imposed a cut-off of functional relevance on the 
Spearman correlation coefficient in absolute value of 0.2 based on previously published 
methodology (236).  
miRNA Transfection  
MDA-MB-231, MDA-MB-436, and BT-20 cells were plated at a density of 1.5 × 105 
cells/well in six-well plates and treated with either miR-484 (100 nM), or control miRNA 
mimic or inhibitor (100 nM) (Ambion) with the addition of HiPerFect transfection reagent 
(Qiagen) in Opti-MEM serum free media according to the manufacturer’s instructions. 
After 6 h of transfection, cultured media was substituted with DMEM supplemented with 
10% FBS for up to 48 h. 
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Cell viability 
Cell viability of MDA-MB-231, MDA-MB-436, BT-20, and MCF-10A cells was analyzed 
using MTS assay [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H tetrazolium] as previously described (237).  Cells were seeded in a 
density of 1 to 2 × 103 cells/well in 96-well plates.  After overnight incubation, the cells 
were treated with miR-484 inhibitor or control inhibitor miRNA (Ambion).  We determined 
the cell viability by measuring the optical density at 490-nm wavelength in a VMax kinetic 
enzyme-linked immunosorbent assay microplate reader (Molecular Devices) at 24, 48, 
and 72 hours 
Colony formation assay 
The effect of miR-484 on TNBC cell proliferation was evaluated by the clonogenic assay.  
MDA-MB-231, MDA-MB-436, and BT-20 cells were seeded at low density (500 cells/well) 
in 12-well plates.  After overnight incubation, the cells were treated with either control 
inhibitor miRNA or miR-484 inhibitor and cultured for approximately 10-14 days.  Colonies 
were stained with crystal violet, and quantified with Image J software (National Institutes 
of Health, Bethesda, MD).  Each experiment was independently triplicated. 
Cell motility and invasion assays 
Cell motility and migration was analyzed by an in vitro wound healing assay.  TNBC cells 
(MDA-MB-231, MDA-MB-436, and BT-20) were plated at a density of 1.5 × 105 cells/well 
in six-well plates.  The following day cells were transfected with the control miRNA 
inhibitor or  miR-484 inhibitor.  After 48h, as the cells reached ~80% confluence, a single 
scratch was made, and cells were imaged at 0h and subsequent 12h time points, using 
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a phase contrast microscope (Nikon Eclipse TE-200-U) to measure the wound width.  
Wound healing was measured as percentage open area of the wound by Image J 
software.  All experiments were independently repeated three times. 
We evaluated TNBC cell invasion utilizing matrigel coated transwell inserts (Corning).  
After 48h transfection with either miR-484 inhibitor or control miRNA inhibitor MDA-MB-
231, MDA-MB-436, and BT-20 cells (4 × 104) were collected in serum free  medium and 
added to the upper chamber of the transwell inserts, allowing cell invasion toward the 
lower chamber which contains serum positive media (10% FBS).  After 24h, invaded cells 
at the bottom of the inserts were fixed, stained with Hema 3 (Thermo Scientific), and 
counted using a light microscope (Nikon Eclipse TE-200-U) at 10X magnification.  
Invaded cells were counted in five fields per slide and all experiments triplicated. 
Cell cycle analysis 
TNBC cells were transfected as previously described with miRNA inhibitors or control 
inhibitor.  After 48h treatment, cells were collected and washed in PBS and fixed in 75% 
ethanol overnight.  The following day cells were centrifuged and resuspended in PBS 
containing 50 μg/ mL propidium iodide (PI) and 100 U/mL of RNAse A.  Samples were 
incubated in the dark for 30 minutes at a temperature of 37ºC prior to flow cytometry 
analysis. The number of cells in each phase of the cell cycle was determined by FlowJo 
Software.  All experiments were independently triplicated. 
 
 
 
Methods 
 
 
41 
 
Analysis of apoptosis 
Apoptosis was assessed by an Annexin V assay.  TNBC cells were seeded in 6 well 
plates (1.5 X105/well) and transfected with either control inhibitor or miR-484 inhibitor 
(100nM) for 48 h.  Cells were then collected and stained with Annexin V/propidium iodide 
(PI) according to the manufacturer’s protocol (BD Pharmingen FITC–Annexin V kit, San 
Diego, CA).   We determined the number of apoptotic cells by flow cytometry using 
CellQuest Pro software (BD Biosciences).  This assay is based on the binding of  Annexin 
V to membrane phospholipids of the apoptotic cells that are translocated from the inner 
to the outer the membrane in apoptotic cells (238).  Apoptosis was also confirmed, by 
detecting the cleavage of caspase-3, caspase-8, caspase-2, and PARP by Western 
blotting. 
Reverse phase protein array (RPPA) 
We performed the RPPA analysis at the Functional Proteomics RPPA Core Facility of 
The University of Texas MD Anderson Cancer Center according to the method described 
previously (239).  MDA-MB- 231 cells were plated in six well plates at a density of 1.5 × 
106 cells/well and transfected with either miR-484 mimic or control miRNA (100 nM) for 
48h. Cells were collected in 100 μl of lysis buffer supplemented with protease and 
phosphatase inhibitors (Roche Applied Science).  Samples were centrifuged at 14,000 X 
g for 30 minutes at a temperature of 4°C.  Supernatants were collected, and total proteins 
concentration was determined by Pierce BCA protein assay kit.  Protein concentrations 
were adjusted to a concentration of 1.0 μg/μl by the addition of lysis buffer.  4XSDS 
Sample Buffer was mixed with β‐mercaptoethanol (β‐Me) at a ratio of 9:1.  Cell lysates 
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were then mixed with 4× SDS sample buffer + β-Me mixture at a ratio of 3:1.  Samples 
were boiled for 5 minutes and stored at -80ºC prior to submission to the RPPA Core 
Facility.  
Luciferase reporter assay 
pEZX-MT06 miRNA reporter vectors containing the binding sites for miR-484 in the 3’-
UTR of HOXA5 and the luciferase gene (GeneCopoeia) were transfected into MDA-MB-
231 and MDA-MB-436.  As a control for target specificity, we transfected pEZX-MT06 
miRNA reporter vectors containing one point mutation at the miR-484 binding site 
(GAGCCTG> GCTACAG) into  MDA-MB-231 and MDA-MB-436 cells.  Cells were plated 
(5×104 cells/well) in a 24-well plate and incubated overnight.  The following day cells were 
co-transfected with the pEZX-MT06 vector (200 ng) and either 100 nM miR-484 mimic or 
control miRNA.   After 48h, firefly luciferase activity was determined by utilizing Luc-Pair 
miR Luciferase Assay (GeneCopoeia) and measurements were normalized to Renilla 
luciferase activity. 
Western blot analysis   
TNBC cells (MDA-MB-231, MDA-MB-436, and BT-20) were treated with miR-484 inhibitor 
or control inhibitor miRNA (100nM) and cells were collected after 48h transfection.  
Lysates were prepared in lysis buffer supplemented with protease and phosphatase 
inhibitors and samples were centrifuged at 14,000 × g for 30 min at a temperature of 4°C. 
Supernatants were collected and analyzed for protein concentration by using the Pierce 
BCA protein assay kit (Thermo Scientific).  Protein samples (40µg) were separated by 
SDS-PAGE on a 4%–15% gradient polyacrylamide gels (Bio-Rad), and subsequently 
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electro-transferred to polyvinylidene difluoride membranes.   Membranes were blocked 
with 5% milk in TBST, rinsed, and then incubated with primary antibodies overnight at 
4ºC.  The following day membranes were rinsed and incubated with their corresponding 
HRP-conjugated secondary antibodies.  GAPDH expression levels were detected as 
loading control.  Antibodies used in this study are listed in the appendix in Table 3.  
HyGLO Chemiluminescent Reagent (Denville Scientific) was used to detect the 
expression levels of the selected proteins and immunoblots were imaged by Fluor Chem 
8900 imager and using Alpha Imager software (Alpha Innotech).  All experiments were 
independently triplicated. 
RNA isolation and quantitative real time polymerase chain reaction (qRT-PCR) 
For mRNA and miRNA detection, first we isolated total RNA using the miRNeasy Mini Kit 
(Qiagen) according to the manufacturer’s protocol.  Subsequently, RNA concentration 
and purity was determined spectrophotometrically (260 and 280 nm UV absorbance) by 
Epoch microplate reader (BioTek Instruments).  For miRNA expression, 1µg of total RNA 
was reverse transcribed to complementary DNA (cDNA) using the qScript microRNA 
cDNA Synthesis Kit (Quanta BioSciences) according to manufacturer’s instructions.  miR-
484 expression was detected by using miRNA primers (Quanta Bio Sciences) by 
quantitative real time polymerase chain reaction (qRT-PCR) and utilizing the PerfeCTa 
microRNA Assay Kit (Quanta Bio Sciences).  The expression levels of miR-484 were 
normalized to expression levels of U6 small nuclear RNA (RNU6; Quanta Bio Sciences), 
as an endogenous control. 
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For HOXA5 mRNA quantification, first we reverse transcribed total RNA to cDNA using 
Revert Aid First Strand cDNA Synthesis Kit (Thermo Scientific) following the 
manufacturer’s instructions.   Then HOXA5 gene expression was measured with the iQ 
SYBR Green Supermix qPCR Kit (Bio-Rad).  GAPDH expression levels were determined 
as endogenous control.  The sequences of the forward and reverse primers for HOXA5 
and GAPDH are listed in the appendix in Table 4.  Relative expression levels were 
analyzed by the comparative threshold cycle (2-ΔΔCt) method. 
HOXA5 gene overexpression  
MDA-MB-231 cells were transfected with lentiviral plasmids containing the specified 
lentiviral vector for HOXA5 (NM_019102.3) with the CMV promoter (LPP-F0180-Lv105; 
GeneCopoeia, Rockville, MD) or the mock vector (LPP-NEG-Lv103; GeneCopoeia) 
according to the manufacturer’s instructions.  HOXA5 protein expression was then 
verified by Western blotting.  
Orthotopic xenograft TNBC tumor models 
For our animal study we obtained female nude athymic mice from M.D. Anderson Cancer 
Center.  We performed our animal study according to an experimental protocol approved 
by the M.D. Anderson Institutional Animal Care and Use Committee.  TNBC cells (MDA-
MB-231 and MDA-MB-436) were injected into the mammary fat pad of each mouse at a 
density of 2 × 106 in 20% matrigel.  Approximately two weeks after TNBC cell injection, 
as tumor volume was in a range of 3-5 mm, we initiated our liposomal-miRNA treatment.  
Mice were treated with either miR-484 inhibitor or control miRNA inhibitor (0.15 
mg/kg≈4μg/mouse) delivered intravenously through the tail vein, once every 4 days for 4 
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weeks (total of eight i.v. injections). We monitored tumor growth, by weekly 
measurements of tumor volumes using an electronic caliper.  At the end of the 
experimental protocol, we euthanized the mice with CO2 and determined their weight to 
measure tumor growth.  Tumor tissues were dissected for further analysis by 
immunohistochemistry, TUNEL (terminal deoxynucleotidyl transferase–mediated dUTP 
nick end labeling), western blot, and qRT-PCR. 
Preparation of miRNA nanoparticles  
For in vivo targeting of miR-484, we incorporated anti-miR484 oligonucleotides into 
liposomal nanoparticles which were composed of dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) and pegylated distearoylphosphatidylethanolamine (DSPE-
PEG-2000) (AvantiLipids) according to our previously described protocol (161).   
Immunohistochemistry 
The effect of miR-484 inhibition on TNBC cell proliferation and angiogenesis in vivo was 
determined by immunostaining tumor sections for Ki-67 and CD31 respectively according 
to the manufacturer’s protocol.  Formalin-fixed paraffin-embedded tumor tissues sections 
were deparaffinized and dehydrated, then incubated in Dako (for antigen retrieval) at 
95°C for 40 minutes.   Slides were then blocked with endogenous peroxidases with 
methanol supplemented with hydrogen peroxide (3%) for 15 min, and then incubated with 
primary antibodies for Ki-67 or CD31 overnight at a temperature of 4°C.  The following 
day, slides were incubated with secondary antibodies for 1 hour at room temperature.  
Tumor sections were then counterstained with hematoxylin for approximately 30 seconds 
and analyzed by light microscope (Nikon Eclipse TE-200-U). 
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Evaluation of in vivo apoptosis (TUNEL assay) 
We evaluated the effect of miR-484 inhibition on TNBC apoptosis in vivo, by measuring 
the nuclear DNA fragmentation using the TUNEL assay kit (Promega) according to the 
manufacturer's recommended protocol.  Tumor sections from mice treated with either 
control inhibitor or miR-484 inhibitor were incubated with biotin-dUTP and terminal 
deoxynucleotidyl transferase for 1h.  Next, we incubated tissue sections with fluorescein 
conjugated avidin in the dark for half an hour, and then counterstained with Hoechst 
33342 dye (Thermo Scientific) DNA.  TUNEL positive cells were then determined in five 
separate fields for each slide using an inverted fluorescence microscope.   
 
Statistical analyses 
 
Unless otherwise stated, data is expressed as means ± standard deviations (SDs) of 
three independent experiments.  We analyzed our data by the two tailed Student t-test to 
compare significant differences between means of data sets, and p-values indicate the 
probability of the means being significantly different, where *p≤0.05, **p≤0.01, ***p≤0.001, 
****p ≤0.001.  Data analysis was performed by Graph Pad Prism software (version 6.02) 
for student t-Test and analysis of variance (ANOVA). 
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miR-484 inhibition decreases cell viability & proliferation in TNBC cells  
Given the observed upregulation of miR-484 in TNBC patients and cells lines, we sought 
to determine the role of miR-484 in TNBC cells in vitro by various functional assays.  First, 
we verified successful transfection efficiency and found that miR-484 inhibitor transfected 
cells (MDA-MB-231) showed significant downregulation of miR-484 levels compared to 
control inhibitor transfected cells, while cells treated with miR-484 mimic had significant 
upregulation of miR-484 levels compared to control mimic treated cells (Fig. 8).  Next, we 
examined the short-term effects of miR-484 on cell proliferation, by the MTS assay on 
three different TNBC cells (MDA-MB-231, MDA-MB-436, BT-20) and normal mammary 
epithelial cells (MCF-10A), treated with either miR-484 inhibitor or control inhibitor for 24, 
48, and 72h.  Our results showed that miR-484 inhibition significantly decreased cell 
viability in TNBC cells at the indicated time points (Fig. 9, p≤0.0001), while no significant 
decrease in cell viability was observed in normal mammary epithelial cells MCF-10A (Fig. 
9). 
Furthermore, we determined the long-term effect of miR-484 on cell proliferation by the 
colony formation assay in MDA-MB-231, MDA-MB-436, and BT-20 cells.  Inhibition of 
miR-484 (25nM) significantly decreased colony formation in all TNBC cell lines (MDA-
MB-231: 41.94% ±10.07 p= 0.0099; MDA-MB-436: 44.19% ±10.66; p= 0.0119; BT-20: 50 
% ± 6.193 p=0.0051) compared to cells treated with control inhibitor (Fig. 10).  Moreover, 
treatments of TNBC cells (MDA-MB-231 and MDA-MB-436) with miR-484 mimic 
significantly increased cell viability and proliferation by the MTS assays and colony 
formation assays respectively (Fig. 11 & 12), suggesting miR-484 induces cell 
proliferation in TNBC cells.   
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Figure 8: miR-484 inhibitor decreases the expression of miR-484 and miR-484 
mimic leads to increased miR-484 expression.  MDA-MB-231 cells were treated with 
either miR-484 inhibitor or miR-484 mimic or control miRs (inhibitor or mimic) at 100nM for 48h.  
miR-484 expression levels were analyzed by qRT-PCR and normalized to U6.   
 
N
T
C
t l
 m
im
i c
C
t l
 i
n
h
i b
i t
o
r
m
i R
- 4
8
4
 i
n
h
i b
i t
o
r
m
i R
- 4
8
4
 m
im
i c
0
1  1 0 - 4
2  1 0 - 4
3  1 0 - 4
3  1 0 - 3
4  1 0 - 3
5  1 0 - 3
6  1 0 - 3
1  1 0 0
3  1 0 0
5  1 0 0
R
e
la
t
iv
e
 m
iR
 4
8
4
 E
x
p
r
e
s
s
io
n
 L
e
v
e
ls
Results 
 
 
51 
 
 
 
 
 
 
Figure 9: Inhibition of miR-484 decreases cell viability in TNBC cells.  Effects of miR-
484 inhibition on cell viability was assessed in MDA-MB-231, MDA-MB-436, BT-20, and MCF-
10A cells treated with 50nM miR-484 inhibitor or control inhibitor for 24, 48, and 72h and examined 
by the MTS assay.  The data are means ± SDs. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. 
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Figure 10: Inhibition of miR-484 decreases colony formation in TNBC cells.  Effects 
of miR-484 inhibition on colony formation of MDA-MB-231, MDA-MB-436, and BT-20 cells.  
Colony percentage was normalized to the number of colonies formed by cells transfected with 
negative control miRNA.  Data is expressed as means ± SDs. *p≤0.05, **p≤0.01. 
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Figure 11: Ectopic overexpression of miR-484 increases cell viability in TNBC cells.  
MDA-MB-231 and MDA-MB-436 cells were treated with either miR-484 mimic or control mimic 
(50nM) for 24, 48, or 72 hrs.  miR-484 treatment significantly increased cell viability in TNBC cells. 
Data = means ± SDs *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.  
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Figure 12: Ectopic overexpression of miR-484 increases proliferation in TNBC 
cells.  miR-484 increases cell proliferation in TNBC cells.  Cells were treated with miR-484 mimic 
or control mimic and the number of colonies were counted after 10 days using image J software.  
The data are means ± SDs. *p≤0.05, **p≤0.01, ***p≤0.001. 
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miR-484 promotes cell cycle progression in TNBC cells 
Deregulation of the cell cycle is often observed in many tumors, which can result in 
uncontrolled cell proliferation, further promoting the process of tumorigenesis (240).  The 
cell cycle is composed of sequential, tightly regulated events, that drive DNA replication 
and cell division (241).    Briefly, the cell cycle is divided into 4 main phases: S phase, for 
DNA synthesis, M phase, in which mitosis occurs, and two gap phases G1 and G2.   Some 
differentiated cells may also enter a period of prolonged quiescence called G0 before 
entering G1 (242).  Transitions between different phases of the cell cycle is regulated by 
changes in the activity of specific cyclins and cyclin dependent kinases (CDKs) (240).  In 
particular, the G1/S transition is a critical cell-cycle event that may be dyregulated in BC 
(243).  This phase is predominantly under the control of cyclin D–CDK4/6 and cyclin E– 
CDK2, and can be negatively regulated by CDK inhibitors such as p21 and p27 (244).   
Considering the effect of miR-484 on TNBC cell proliferation, we determined the role of 
miR-484 on cell cycle progression.  TNBC cells (MDA-MB-231, MDA-MB-436, and BT-
20) were treated with miR-484 inhibitor or control inhibitor and subjected to flow cytometry 
for cell cycle analysis.  Treatment of MDA-MB-231, MDA-MB-436, and BT-20 cells with 
miR-484 inhibitor (100nM) significantly increased the percentage of cells in G0/G1 phases 
of the cell cycle (MDA-MB-231 by 6.83%, MDA-MB-436 by 9.43%, and BT-20 by 9.61%) 
and significantly decreased the percentage of cells in S phase (MDA-MB-231 by 13.71%, 
MDA-MB-436 by 9.65%, and BT-20 by 18.32%) compared to cells treated with control 
inhibitor miRNA (Fig. 13).  Moreover, we determined the mechanism by which miR-484 
regulates the cell cycle by determining the expression of G1/S phase checkpoint 
regulators by Western blot analysis.  Our results indicated that miR-484 inhibition reduced 
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the expression Cyclin D1, Cyclin E, CDK 2, CDK4, CDK6, and induced cyclin dependent 
kinase inhibitors  p21 and p27 in TNBC cells (Fig. 14), further suggesting that miR-484 
increases cell proliferation and cell cycle progression in TNBC. 
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Figure 13: miR-484 inhibition induces G1/S phase cell cycle arrest in TNBC.  Cell 
cycle analysis after treatment with miR-484 inhibitor or negative control miRNA shows that miR-
484 inhibition increased the percentage of TNBC cells in G1 phase and decreased the percentage 
of cells in S phase. Data are represented as mean ± SD of three independent experiments. 
*p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001. 
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Figure 14: miR-484 regulates G1/S phase checkpoint mediators in TNBC.  Expression 
levels of CDK2, CDK4, CDK6, cyclin D1, cyclin E1, p21, and p27 were determined by Western 
blot in TNBC cells (MDA-MB-231, MDA-MB-436, and BT-20) transfected with miR-484 inhibitor 
or negative control miRNA. GAPDH was used as a loading control.  
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Inhibition of miR-484 reduces cell motility and invasion in TNBC cells  
Metastasis is the primary cause of cancer related mortality and involves dissemination of  
the primary tumor to the surrounding tissues and distant organs (245).  Each step of the 
metastatic cascade is dependent on the motility and invasive capacity of tumor cells 
including their ability to penetrate the basement membrane, escape from the primary 
tumor site, migrate through the lymphatic and blood vessels, and finally intravasate or 
extravasate to the distant organs (246). 
Considering the significant association of miR-484 with poor OS in BC patients, we 
determined the role of miR-484 on cell motility and invasion in TNBC cells by performing 
in vitro wound healing and invasion assays.  MDA-MB-231, MDA-MB-436, and BT-20 
cells were transfected with either control inhibitor or miR-484 inhibitor (100 nM) for 48h 
and subsequently wound healing assay was performed as previously described (237).  
We observed that TNBC cells treated with miR-484 inhibitor showed decreased wound 
healing percentage compared to control inhibitor transfected cells (MDA-MB-231 
p=0.0109; MDA-MB-436 p= 0.0118, and BT-20 p=0.009) (Fig.15), suggesting that miR-
484 increases TNBC cell motility.  Furthermore, we determined the role of miR-484 on 
TNBC cell invasion using transwell invasion assay. Our results also showed that miR-484 
inhibition decreased the number of invading cells compared to control miRNA-inhibitor 
treatment in MDA-MB-231 (p=0.0006), MDA-MB-436 (p=0.0002), and BT-20 cells 
(p=0.0019 (Fig. 16), suggesting that miR-484 expression increases the invasiveness of 
TNBC cells.  Moreover, overexpression of miR-484 in MDA-MB-231 and MDA-MB-436 
cells with miR-484 mimic significantly increased cell motility and invasion compared to 
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control cells, providing further evidence that miR-484 promotes cell motility and invasion 
(Figures 17 and 18). 
 
Regulation of cell migration and invasion in cancer cells is mediated by signaling 
pathways, including SRC and focal adhesion kinase pathway (FAK) (247).  The SRC 
family of non-receptor protein tyrosine kinases are known to play critical roles in cell 
proliferation, migration/invasion, and metastasis in many cancers including BC (248).  Src 
functions by mediating multiple downstream effects of receptor tyrosine kinases, such as 
the EGFR family (249, 250), and its expression is reported to be elevated in many solid 
tumors, including BC (251) (249).  Increased Src activity can be attributed to an increase 
in its transcription or to overexpression of its upstream regulators such as EGFR, HER2, 
platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor 
(FGFR), as well as integrins, and focal adhesion kinase (FAK) (252-254).   Focal adhesion 
kinase (FAK), is another critical mediator of cell adhesion and migration, which can be 
recruited by intergrins to form a dual complex with Src that promotes cell motility and 
survival (255).  Thus, both Src and FAK may be important therapeutics targets in 
tumorigenesis (256).  Figure 19 shows that miR-484 inhibition in MDA-MB-231, MDA-MB-
436, and BT-20 cells results in a significant reduction in both p-SRC (Tyr-416) and p-FAK 
(Tyr-397) levels which is consistent with the previously described interaction between Src 
and FAK in tumor cells (256). 
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Figure 15: miR-484 inhibition reduces cell motility in TNBC.  MDA-MB-231, MDA-MB-
436, and BT-20 cells were treated with miR-484 inhibitor, or negative control inhibitor (100nM), or 
did not undergo transfection (NT), and cell motility was assessed by the wound healing assay.  
Images are shown at 0 and 48h time points. Wound closure percentage was normalized to 
untreated cells. Data is shown as means ± SDs. 
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Figure 16: miR-484 inhibition reduces TNBC cell invasion. MDA-MB-231, MDA-MB-
436, and BT-20 cells were treated with miR-484 inhibitor or negative control inhibitor miRNA 
(100nM) or not treated (NT).  After 48h of transfection, cells were transferred to matrigel-coated 
transwell inserts. 24h later the invaded cells were quantified and normalized to the number of 
invaded cells from the NT group.  Data represents means ± SDs from triplicate experiments 
(***p≤0.001).  
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Figure 17: miR-484 overexpression increases cell motility and invasion in TNBC. 
MDA-MB-231, MDA-MB-436 cells were treated with miR-484 mimic, or negative control mimic, 
and cell motility was assessed by the wound healing assay.  Images were taken at 0 and 48h. 
The percentage wound healing was quantified and shown on the right panel as means ± SDs 
(**p≤0.01). 
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Figure 18: Ectopic over-expression of miR-484 increases invasion in TNBC cells.  
MDA-MB-231, MDA-MB-436 cells were transfected with miR-484 mimic or control mimic for 48h 
and transferred to matrigel-coated transwell inserts and incubated for an additional 24h. The 
number of invaded cells per field was quantified and shown as mean ± SDs from triplicate 
experiments (***p≤0.001). 
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Figure 19: miR-484 inhibition reduces p-SRC and p-FAK expression in TNBC cells.  
Expression levels of p-SRC, SRC, p-FAK, FAK were determined by Western blot in TNBC cells 
treated with miR-484 inhibitor (100nM) for 48h or negative control miRNA. GAPDH was used as 
a loading control.   
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miR-484 Inhibition induces apoptosis in TNBC cells 
Given the observed effect of miR-484 inhibition on reducing cell growth in TNBC, we 
subsequently investigated its role in programmed cell death.  Programmed cell death I, 
or apoptosis, is mainly induced by two main mechanisms: intrinsic or mitochondrial 
apoptosis; and extrinsic or death receptor mediated apoptosis (257).  Both pathways lead 
to the activation of the caspase family of cysteine proteases, which eventually leads to 
specific morphological features, typical of apoptosis, such as  chromatin condensation, 
DNA fragmentation, membrane blebbing, and finally complete cell lysis (258).  Many 
studies have shown that aberrantly expressed miRNAs are related to apoptosis evasion 
in tumor progression and tumorigenesis and drug resistance (259). 
MDA-MB-231, MDA-MB-436 and BT-20 cells were treated with either miR-484 inhibitor 
or control inhibitor for 48h.  Apoptosis following miR-484 inhibition was determined by 
Annexin V/ Propidium Iodide (PI) staining, followed by flow cytometry (FACS) to 
determine the percentage of apoptotic cells.  The percentage of both early and late 
apoptotic cells was significantly higher in TNBC cells treated with miR-484 inhibitor 
compared to control cells (MDA-MB-231 p=0.0002, MDA-MB-436 p=0.0014, BT-20 
p=0.0036), suggesting that miR-484 inhibition induces cell death (Fig. 20).  Furthermore, 
we confirmed apoptosis induction by determining the expression of apoptosis-related 
proteins such as PARP, caspase-3, caspase-2, caspase-8 by Western blot (Fig. 21).  
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Figure 20: Inhibition of miR-484 induces apoptosis in TNBC cells. TNBC cells were 
treated with either miR-484 inhibitor or control inhibitor (100nM) for 48h, and stained by Annexin 
V/PI followed by flow cytometry to determine the number of apoptotic positive cells.  
Representative percentages are the sum of both early and late apoptosis.  Data are represented 
as means ± SD. *p≤0.05.  All experiments were independently triplicated.  
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Figure 21: miR-484 inhibition regulates the expression of apoptotic markers in 
TNBC. Expression levels of apoptotic markers (PARP, Caspase-3, Caspase-2, Caspase-8) in 
MDA-MB-231 and MDA-MB-436 cells were detected by WB after 48h transfection with miR-484 
inhibitor or negative control inhibitor miRNA (100nM). GAPDH was used as a loading control.  
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HOXA5 is a predicted target for miR-484  
We retrieved miRNA-target interaction predictions for miR-484 from miRWalk2.0  
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) that integrates results from 
twelve different predictive algorithms (DIANA-microTv4.0, DIANA-microT-CDS, 
miRanda-rel2010, mirBridge, miRDB4.0, miRmap, miRNAMap, PicTar2, PITA, RNA22v2, 
RNAhybrid2.1, and Targetscan6.2).  We selected the 147 targets which were predicted 
by at least nine algorithms (3/4 of the total number of programs checked).  Among them 
we chose the 16 experimentally validated targets (listed in Appendix Table 5) as retrieved 
from miRWalk2.0.  Based on a literature search, we focused on HOXA5 as it was 
previously shown to have a tumor suppressive role in BC (260, 261).   The predicted 
binding site for miR-484 on HOXA5 3’-UTR is shown in Figure 22, and this binding site 
was also found to be highly conserved among many species (Fig. 23). 
 
 
 
Figure 22:  Predicted binding site of miR-484 and HOXA5 3’-UTR. 
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Figure 23: miR-484 and HOXA5 binding sites are highly conserved across many 
species. 
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High miR-484 expression is correlated with low HOXA5 expression in BC patients 
& cell lines 
The homeobox genes (HOX genes) are composed of 39 members, organized in four 
clusters (A, B, C, and D), located on chromosomes 7, 17, 2, and 12, respectively (262).  
HOXA5 belongs to the cluster A family of HOX regulatory genes.  The homeobox 
sequence (183 nt) of HOX genes encode homeoproteins that can act as transcription 
factors, to either activate or repress the expression of downstream effector target genes 
(263, 264).  Numerous studies during the last several decades, have highlighted the 
importance of HOX genes in  normal tissues, as well as in many clinical diseases and 
carcinomas (265).  The HOX family genes play fundamental roles in the anterior-posterior 
patterning during embryonic development (266, 267).   They have also been shown to be 
aberrantly expressed and/or mutated in many cancers, including leukemia, colon, 
prostate, breast, and ovarian cancers (268).  In particular, homeobox A5 (HOXA5) has 
been shown to be a key regulator of cell differentiation and organogenesis.  HOXA5 has 
been implicated in the development of the axial skeleton, as wells are respiratory system, 
mammary glands, and digestive tracts (269).  In the context of BC, HOXA5 expression 
was found be reduced in more than 60% of BC cell lines, partially due to hypermethylation 
of its promoter region (261).  Additionally, HOXA5 has been shown to induce apoptosis, 
both in a p-53 dependent or caspase 2 and 8 dependent manner in BC cells (260, 261).  
Furthermore, the loss of HOXA5 expression was shown to lead to the functional activation 
of Twist, a negative regulator of p53 (270), resulting dysregulation of the cell cycle and 
promotion of breast carcinogenesis (271).  Collectively, these studies indicate that 
HOXA5 may serve as a tumor suppressor gene in BC.    
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To evaluate the potential interaction between miR-484 and HOXA5, we analyzed the 
TCGA database of BC patients (n=833) and performed a spearman rank correlation 
(p≤0.00001, R=0.31) and found that miR-484 was inversely correlated with HOXA5 
expression in patients’ tumors (Fig. 24).  Furthermore, HOXA5 protein expression was 
found to be reduced in all BC cell lines (MDA-MB-231, MDA-MB-436, MDA-MB-453, BT-
20, MDA-MB-453, MDA-MB-361, MCF-7, and T-47)  compared with normal immortalized 
breast epithelial cell lines (MCF-10A and HMEC) by Western blot analysis (Fig. 25), 
suggesting an inverse relationship between  HOXA5 and miR-484  expression, and the 
possibility that miR-484 regulates HOXA5  mRNA expression. 
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Figure 24: miR-484 and HOXA5 expression levels are inversely correlated in BC 
patients. Spearman correlation analysis showed a negative and significant correlation between 
miR-484 and its target gene HOXA5 in BC patients (n=833).  R=0.31, p≤0.0001. 
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Figure 25: miR-484 and HOXA5 expression levels are inversely correlated in BC cell 
lines. A) HOXA5 expression levels are lower in BC cell lines compared to normal breast epithelial 
cells MCF-10A and HMEC.  Basal HOXA5 expression levels were analyzed by WB and GAPDH 
was used as loading control. B) miR-484 basal expression levels were assessed by qRT-PCR.  
U6 was used as internal control. C) Pearson correlation analysis showing a negative and 
significant correlation between miR-484 and HOXA5 in BC cells.  R=0.8, p=0.041. 
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miR-484 directly binds to the 3’-UTR of HOXA5 to regulate its expression   
miRNAs are involved in post-transcriptional regulation of gene expression mainly by 
directly binding of the 3’-UTR of their target mRNAs to negatively regulate their 
expression (72).  To evaluate the effect of miR-484 on HOXA5 gene and protein 
expression in TNBC cells, we transfected MDA-MB-231, MDA-MB-436, and BT-20 cells 
with miR-484 inhibitor (100nM) or negative control inhibitor for 48h.  Inhibition of miR-484 
resulted in significant reduction in HOXA5 protein and mRNA expression in the cell lines 
detected by Western blot and qRT-PCR analysis, respectively (Figures 26 and 27).  
Collectively, these results suggests that miR-484 suppresses HOXA5 protein and mRNA 
expression levels in TNBC cells.   
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Figure 26: miR-484 reduces HOXA5 protein expression levels in TNBC cells.  
MDA-MB-231, MDA-MB-436, and BT-20 cells were treated with miR-484 mimic or control mimic 
(100nM) for 48h and cell lysates were analyzed for HOXA5 expression by WB analysis.  GAPDH 
was used as loading control. 
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Figure 27: miR-484 reduces HOXA5 mRNA expression levels in TNBC cells.  Cell 
lines were analyzed for HOXA5 mRNA levels by qRT-PCR 48h after miR-484 transfection.  Data 
is represented as fold change normalized to GAPDH expression levels.  *p≤0.05. 
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miR-484 directly binds to HOXA5 3’-UTR to negatively regulate its expression 
To further prove the direct role of miR-484 on HOXA5 mRNA regulation we identified the 
consensus sequences on the 3-UTR region of the HOXA5 gene for binding to miR-484 
and performed a luciferase gene reporter assay.  The human wild type (WT) HOXA5 3’-
UTR was cloned upstream of a firefly luciferase gene in a reporter vector (pEZX-MT06) 
plasmid.  A similar vector containing the mutated sequence (GAGCCTG> GCTACAG) in 
the miR-484 binding site of the HOXA5 3’-UTR-mut (pMSCV–HOXA5-3’-UTR-mut) was 
used as a negative control.  The resulting plasmids were separately transfected into MDA-
MB-231 and MDA-MB-436 cells along with miR-484 mimic or negative control miRNA 
(100nM).  Firefly luciferase activity was measured and normalized to Renilla Luciferase 
activity.  As shown in Figure 28, cells treated with miR-484 and expressing the WT 3’-
UTR of HOXA5 had significant reduction in luciferase activity compared to cells treated 
with control miRNA (MDA-MB-231 p=0.0021 and MDA-MB-436 p≤0.0001).  Moreover, 
cells expressing the pEZX-MT06 miRNA reporter vector containing the mutated miR-484 
binding site (pMSCV–HOXA5-3’-UTR-mut) showed no significant difference in luciferase 
activity between miR-484 and control miRNA transfections.  Thus, our findings suggest 
that miR-484 binds specifically to the WT HOXA5 3’-UTR to negatively regulate its mRNA 
expression. 
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Figure 28: miR-484 directly binds to HOXA5 3’-UTR in TNBC cells.  Luciferase reporter 
assay showing that miR-484 directly binds to the 3’-UTR of HOXA5 luciferase reporter in MDA-
MB-231 and MDA-MB-436 cells. Firefly luciferase activity was normalized to endogenous Renilla 
luciferase activity. Data are represented means ± SDs for three independent experiments. 
*p≤0.05  
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miR-484 mediates its effects through inhibition of  HOXA5 tumor suppressor in 
TNBC cells 
Reduced cell proliferation in cancer  is often associated with concomitant activation of cell 
death pathways and inhibition of cell cycle progression (272).  We have shown that miR-
484 inhibition significantly induces apoptosis and promotes G1/S cell cycle arrest in TNBC 
cells.  Furthermore, HOXA5 expression has been shown to lead to activation of cell death 
pathways (260, 261) and aberrant cell cycle regulation (271).  Therefore, we examined 
the role of HOXA5 in mediating apoptosis in response to miR-484 inhibition.  First, we 
transduced MDA-MB-231 cells with HOXA5-expressing lenti-based vector and control 
empty-vector that lack HOXA5 gene. Light microscopy revealed that HOXA5 
overexpressing cells displayed typical apoptotic morphology such as cell shrinkage and 
appeared denser compared to controls (273) (Fig. 29).  Furthermore, HOXA5 
overexpressing cells showed increased apoptosis by FACS, which was reversed by 
expression of miR-484 mimic (Fig. 30).  This finding was also associated with a reduction 
in HOXA5 expression levels (Fig. 31).  Moreover, HOXA5 overexpression recapitulated 
the effects of miR-484 inhibition on apoptotic markers such as PARP and capase-3 and 
G1/S cell cycle regulators such as Cyclin D1, Cyclin E1, CDK4, and  induced the 
expression of CDK inhibitors p21 and p27 (Fig. 32).  Overall, our findings suggest that 
miR-484 could promote TNBC cell survival through downregulation of HOXA5 tumor 
suppressor gene. 
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Figure 29: HOXA5 overexpressing cells display typical apoptosis morphological 
features.  MDA-MB-231 cells were transduced with lentiviral expression vector incorporating 
WT-HOXA5 (NM_019102.3) (HOXA5-OE) for overexpression of HOXA5 or the mock empty 
vector (EV) (LPP-NEG-Lv103) and examined under the light microscope 48h after transduction. 
HOXA5 overexpressing cells appeared smaller and denser compared to cells expressing control 
empty vector.  Magnification 4X. 
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Figure 30: miR-484 reverses HOXA5 induced apoptosis. MDA-MB-231 cells over-
expressing either HOXA5 or mock empty vector were co-transfected with either miR-484 mimic 
or control mimic (100nM) and collected after 48h.  Cells were stained with Annexin/PI for FACS 
analysis of the apoptotic positive cells. Data are represented as mean ± SD. **p≤0.01. All 
experiments were independently triplicated. 
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Figure 31: miR-484 partially reduces HOXA5 expression in HOXA5 overexpressing 
cells.  MDA-MB-231 cells overexpressing HOXA5 (HOXA5-OE) or expressing control empty 
vector (EV) were treated with either miR-484 mimic or control mimic (100nM) and collected after 
48h.  Cell lysates were analyzed for HOXA5 expression levels by Western blot.  GAPDH was 
used an internal control. 
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Figure 32: HOXA5 overexpression recapitulates miR-484 inhibition on apoptosis 
and cell cycle markers.  MDA-MB-231 cells overexpressing HOXA5 lentiviral vector (HOXA5-
OE) or expressing control empty vector (EV) were treated with either miR-484 mimic or control 
mimic (100nM) and collected after 48h.  The levels of HOXA5, PARP, caspase-3, Cyclin D1, 
Cyclin E1, p27, and p21 were determined by WB.  GAPDH was used as loading control. 
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miR-484 alters multiple proteins/cancer signaling pathways in TNBC: 
To determine the potential signaling pathways that are regulated by miR-484 in TNBC, 
we performed a reverse phase protein array (RPPA) analysis of MDA-MB-231 cells 
treated with either miR-484 mimic or control miRNA. Samples were probed with 304 
proteins, including total and phospho-proteins. Among the proteins that were probed for, 
we found a total of 55 proteins that were significantly upregulated with miR-484 
overexpression compared to controls, and a total of 61 proteins that were significantly 
downregulated with miR-484 treatment compared to controls.  Significantly altered 
proteins after miR-484 transfection are shown in the heat map in Figure 33.  Of particular 
interest to us, we observed significant downregulation of caspase-8 (FCH=-1.09 p-
value=0.11), p53 (FCH=-1.074 p-value=0.014), Bax (FCH=-1.04 p-value=0.031) with 
miR-484 overexpression, and significant upregulation of cyclin D1 (FCH=+1.18 p-
value=0.012) with miR-484 treatment. Furthermore, our ingenuity pathway analysis 
showed that miR-484 overexpression in MDA-MB-231 cells resulted in alteration in many 
signaling pathways related to cell proliferation, apoptosis, and cell cycle regulation (Fig. 
34), which is consistent with our previously mentioned findings.  Figure 35 summarizes 
the findings from our IPA analysis and illustrates the interaction between miR-484 and 
HOXA5 in regulating certain apoptosis related proteins such as PARP and caspases as 
well as cell cycle regulators such as cyclins and CDKs. 
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Figure 33: Overexpression of miR-484 significantly alters multiple proteins 
involved in cancer signaling in TNBC. Heat map of RPPA analysis showing significantly 
altered proteins after miR-484 transfection in MDA-MB-231 cells.  Green color indicates that 
expression levels were reduced with miR-484 treatment compared to control miRNA treatment, 
while red color indicates that the expression levels were increased with miR-484 transfection 
compared to controls. 
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Figure 34: miR-484 overexpression significantly alters multiple cancer signaling 
pathways in TNBC. The pathway annotations obtained by Ingenuity Pathway Analysis (IPA) 
show that ectopic overexpression of miR-484 in MDA-MB-231 cells led to alteration in multiple 
canonical pathways related to cancer.    
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Figure 35: Ectopic overexpression of miR-484 regulates HOXA5 and multiple 
downstream targets in TNBC.  Ingenuity Pathway Analysis (IPA) showing the canonical 
pathways/proteins that were significantly downregulated (green) or upregulated (red) by miR-484 
in TNBC cells. Graphs produced by RPPA analysis of MDA-MB-231 treated with miR-484 or 
control mimic for 72h. 
 
Results 
 
 
90 
 
 
 
 
 
 
 
 
 
 
Aim 3: 
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In vivo therapeutic targeting of miR-484 suppresses growth of orthotopic TNBC 
xenograft tumors and induces HOXA5 expression  
We have shown that miR-484 is upregulated in TNBC cell lines and is associated with 
poor patient survival and prognosis.  Therefore, to demonstrate the in vivo effects of miR-
484 in promoting TNBC tumorigenesis and progression as well as the therapeutic 
potential of targeting this oncogenic miRNA, we inhibited miR-484 in orthotopic MDA-MB-
231 and MDA-MB-436 TNBC mouse models.  Tumor cells (2 X 106 cells/mouse) were 
orthotopicaly injected in into the mammary fat pad of female nude athymic mice (n=5).  
After approximately one week, we injected dimyristoyl-sn-glycero-3-phosphocholine-
based liposomal nanoparticles (237) incorporating anti-miR-484 (0.15 mg/kg, i.v.) once a 
week, for 4 weeks.  At the end of the treatment we evaluated the in vivo effects of miR-
484 downregulation on tumor growth and analyzed for proliferation, angiogenesis, and 
apoptosis by IHC.  Mice treated with miR-484 inhibitor showed decreased expression of 
miR-484 levels in tumors (Fig. 36) compared to control inhibitor, and had a significant 
decrease in tumor volume compared to control mice (Fig. 37) (p≤0.05). 
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Figure 36: Systemic delivery of Anti-miR-484 reduces miR-484 expression levels in 
orthotopic xenograft TNBC mouse models.  MDA-MB-231 and MDA-MB-436 cells were 
orthotopically injected in female nude athymic mice (n=5).  Mice were then treated with either 
control inhibitor or miR-484 inhibitor liposomal nano-particles delivered I.V. once every 4 days, for 
4 weeks.  miR-484 expression levels were analyzed from tumor samples by qRT-PCR.  U6 was 
used as internal control. 
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Figure 37:  In vivo systemic delivery of Anti-miR-484 nanoparticles decreases 
tumor volume in TNBC mouse xenografts.  Tumor volumes were determined once a week 
for 4 weeks and data is represented as means ± SD. *p=≤0.05.  
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To assess the effects of miR-484 inhibition on cell proliferation, angiogenesis, and 
apoptosis, tissue sections were stained with hematoxylin and eosin followed by 
immunohistochemical analysis for Ki-67 expression as a proliferation marker, and CD31 
as a marker for angiogenesis.   Additionally, we analyzed the effects of miR-484 inhibition 
on apoptosis by the Terminal deoxynucleotidyl transferase–mediated dUTP nick end 
labeling (TUNEL) assay which detects nuclear DNA fragmentation in apoptotic cells.  Our 
results showed that mice treated with miR-484 inhibitor had a greater reduction of Ki-67–
positive tumor cells compared to mice treated with control inhibitor (MDA-MB-231 
p=0.0011, MDA-MB-436 p=0.0093) (Fig. 38).  Furthermore, miR-484 inhibition 
dramatically decreased micro-vessel density, as represented by CD31-positive cells, 
compared to control inhibitor miRNA (Fig. 39) in both orthotopic tumor models (MDA-MB-
231 p=0.024, MDA-MB-436 p=0.0192), suggesting that inhibition of miR-484 has an 
antiangiogenic effect in TNBC mouse models. Additionally, miR-484 inhibition 
significantly increased the number of TUNEL-positive cells compared to control inhibitor 
miRNA (Fig. 40) (MDA-MB-231 p=0.0019, MDA-MB-436 p=0.0049), suggesting that miR-
484 inhibition has a pro-apoptotic effect in vivo.  Overall, our findings indicate that miR-
484 inhibition decreased tumor growth in orthotopic TNBC mouse models through 
significant suppression of cell proliferation and angiogenesis and induction of apoptosis. 
Furthermore, we assessed the HOXA5 expression levels by both WB and PCR and 
observed that miR-484 inhibition significantly increased HOXA5 protein and mRNA 
expression levels by Western blot (Fig. 41) and qRT-PCR analysis (Fig. 42) respectively 
in both tumor models, providing further evidence that miR-484 pro-tumorigenic effect in 
TNBC mouse models is mediated by suppression of HOXA5 in TNBC.  
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Figure 38: miR-484 inhibition decreases Ki-67 expression.  Tumor cell proliferation was 
analyzed by determining Ki-67 expression in tumor tissues by immunohistochemistry.  
Magnification X20. 
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Figure 39: miR-484 inhibition decreases CD31 expression.  Tumor tissue sections were 
analyzed for CD31 expression as a micro-vessel density marker by immunohistochemistry. 
Magnification X20. 
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Figure 40: miR-484 inhibition induces TUNEL positive cells in TNBC mouse models.  
Analysis of in vivo apoptosis induction was performed by the TUNEL assay in TNBC tumor 
xenografts. Magnification×20. 
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Figure 41: miR-484 inhibition increases HOXA5 protein expression levels in TNBC 
orthotopic xenografts.  TNBC tumor cell lysates were analyzed for HOXA5 expression levels 
by Western blot analysis. GAPDH was used as a loading control.  
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Figure 42: miR-484 inhibition increases HOXA5 mRNA expression levels in TNBC 
orthotopic xenografts.  RNA was isolated from TNBC tumor samples and analyzed for miR-
484 expression by qRT-PCR.  miR-484 inhibition increase HOXA5 mRNA expression levels in 
TNBC xenograft tumors. Data is represented as fold change normalized to GAPDH as 
endogenous control.
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DISCUSSION: 
Triple negative breast cancer is a very heterogenous and aggressive BC subtype, that 
lacks specific markers (i.e. ER, PR and HER2) for effective targeted therapy (eg. anti-
estrogens, anti-HER2 therapies) (6, 49).  Currently, TNBC has six different genetically 
defined subtypes, making it highly difficult to identify common molecular targets for 
development of targeted therapies (7).  Several gene expression and miRNA profiling 
studies have been carried out in order to identify particular miRNA signatures in TNBC 
patients (274).   Moreover, several miRNAs have been identified to play a crucial role in 
TNBC carcinogenesis, providing a basis for their possible therapeutic application with 
promising results (274).  Thus, the application of miRNA based therapy represents an 
innovative approach, especially for TNBC patients with limited therapeutic options. 
The key findings in our study is that miR-484 is a clinically significant oncogenic miRNA 
that is highly expressed in TNBC patients and is associated with poor OS and prognosis.  
Additionally, we found that miR-484 acts as an onco-miR by directly binding and 
regulating the expression of the tumor suppressor gene HOXA5 in TNBC.  Our study also 
provides the first evidence that in vivo therapeutic targeting of miR-484 by systemically 
injected anti-miR-484 nanoparticles significantly inhibits tumor growth and induces 
HOXA5 expression in TNBC tumor models.   
 
 
 
 
Discussion 
 
102 
 
Significance of miR-484 in Cancer 
Certain miRNAs have been shown to behave either as oncogenic or as tumor suppressor 
miRNAs depending on the cellular context (103).  Such is the case for miR-484, as it has 
been reported to either act as a tumor suppressor or oncogenic miRNA depending on the 
cancer type.   
The potential oncogenic role of miR-484 has been previously reported in renal cell 
carcinoma (RCC), where miR-484 was shown to correlate with drug resistance to 
Sunitinib (tyrosine kinase inhibitor) (275, 276).  Patients expressing high miR-484 levels 
had a median time to progression (TTP) of 5.8 months, whereas patients with low miR-
484 expression had a median TPP of 8.9 months.  Although the exact mechanism of 
action of miR-484 in RCC is not yet elucidated, this study suggests that miR-484 may be 
utilized as a potential predictive biomarker in RCC patients treated with Sunitinib.  
Additionally, Wang and colleagues showed that miR-484 targets mitochondrial fission 
protein Fis1, which is induced by anoxia; thereby inhibiting mitochondrial fission and 
apoptosis in cardiomyocytes and in adrenocortical cancer cells (277).  Furthermore, they 
showed that the transcription factor Foxo3a activated miR-484 expression by binding to 
its promoter region, and that this binding was attenuated by anoxia (277).  Other studies 
have also suggested the clinical significance of miR-484 as a diagnostic biomarker in 
cancer.  For example, miR-484 was found to be a predictive biomarker for prostate cancer 
recurrence (278).  Another study reported that miR-484 is a predictive biomarker that is 
highly expressed in metastatic CRC patients treated with combination 5-
flurouracil/oxaliplatin (279).  However, to our knowledge the mechanism of action of miR-
484 in prostate or colon cancer has not been defined as of yet. 
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On the other hand, miR-484 was reported to act as a tumor suppressor miRNA in cervical 
cancer, leading to suppression of proliferation, migration/invasion, and induction of 
apoptosis in vitro.  Mechanistically, ZEB1 and SMAD2 were identified as miR-484 targets 
using predictive algorithms and miR-484 was shown to reduce their expression levels, 
while overexpression of ZEB1 and SMAD2 reversed the events mediated by miR-484 in 
cervical cancer cells (280).  miR-484 was also reported to be among three miRNAs 
implicated in classifying ovarian cancer patient response to chemotherapy (281).  
Moreover, miR-484 was found to modulate the tumor vasuclature by targeting VEGF-B in 
tumor cells and VEGF-R2 in adjacent endothelial cells (281). 
 
Clinical and Functional Significance of miR-484 in Breast Cancer 
Here we report for the first time that miR-484 is highly expressed in TNBC subtype of BC 
patients compared to non-TNBC and normal subtypes.  Moreover, we found that high 
miR-484 expression is correlated with worse OS and prognosis in BC patients.  In support 
of our findings, a previous study found that miRNA-484 is differentially expressed in 
different clinical and molecular subclasses of invasive BC (234).  Utilizing genome-wide 
data for miRNA/mRNA expression and DNA methylation, an integrated survival analysis 
was performed on 466 BC patients.  This analysis revealed a distinct prognostic 
signature, composed of seven miRNAs, including miR-484, and 30 mRNA genes, and 
was successfully validated on eight other BC cohorts (234).   Furthermore,  Zearo and 
colleagues reported that  miR-484 is significantly upregulated in the serum of early BC 
patients, suggesting its potential as an early diagnostic biomarker in BC (235).  Thus, our 
data, complemented by the previous findings highlight the clinical significance of miR-484 
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as a biomarker in BC, and further demonstrated the significance of miR-484 expression 
in TNBC. 
To our knowledge, we are the first to report the functional role of miR-484 in TNBC.  Our 
in vitro functional assays showed that miR-484 inhibition significantly reduced TNBC cell 
viability, cell proliferation, motility/migration, while inducing G1/S cell cycle arrest, and 
apoptosis.   Moreover, opposite effects were observed by the treatment of cells with miR-
484 mimic, providing further evidence for the oncogenic role of miR-484 in TNBC.  In 
support of our findings, Ye and colleagues recently showed that miR-484 is implicated in 
cell proliferation and cell cycle regulation.  In their study, miR-484 overexpression 
promoted cell proliferation and cell cycle progression by targeting cytidine deaminase 
enzyme in gemcitabine resistant BC cells (282).  We also utilized RPPA as an unbiased 
platform to provide us with the proteomic analysis in order to understand the potential role 
of miR-484 in vitro after its overexpression in TNBC cells (239).  The comprehensive 
analysis of the RPPA data unraveled the link between miR-484 and signaling pathways 
involved in apoptosis and cell cycle progression, which we further confirmed by western 
blot analysis. 
 
Deregulated Expression of Tumor Suppressor HOXA5 by Onco-miR-484 in Breast 
Cancer  
 
HOX genes are defined by a DNA-binding domain called the homeodomain which 
encodes for transcription factors that can function to either upregulate or repress the 
transcription of downstream targets.  Numerous studies over the past several decades 
have demonstrated that HOX genes play a crucial role in the  normal temporo-spatial limb 
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(283) and organ (284-286) development along the anterior-posterior (A-P) axis (287).  
Additionally, several studies have also revealed that HOX genes can be aberrantly 
expressed or mutated in many cancers, acting to either promote or suppress tumor 
development (288, 289), by regulating processes such as cell proliferation, angiogenesis, 
apoptosis, and tumor metastasis (290-293).  This aberration could be mainly attributed to 
three main mechanisms: 1) temporospatial deregulation, where HOX gene expression in 
tumors is temporospatially different than in normal tissues; 2) gene dominance, where 
HOX genes are expressed at higher levels in cancer tissues versus normal; and 3) 
epigenetic deregulation in which HOX genes are either downregulated or silenced in 
tumors (288). 
 
HOXA5 is a member of the cluster A family of HOX genes located on chromosome. 
7p15.2 (289).  HOXA5 has been shown to be a key regulator of cell differentiation and 
organogenesis particularly in the axial skeleton, respiratory system, mammary glands, 
and digestive tracts (269).  HOXA5 has also been shown to regulate many processes in 
carcinogenesis namely in breast, lung, colon, ovarian, and hematological malignancies 
(269).   
 
Previous literature suggest that HOXA5 may function as a tumor suppressor in BC.  
HOXA5 expression has been shown to be decreased in almost 60% of BC cell lines, 
which is partially attributed to hypermethylation of the HOXA5 promoter region (261).  
Moreover, reduced HOXA5 expression was found to be correlated with progression to 
higher-grade BC stages (261, 294), further supporting our findings of the association of 
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low HOXA5 with poor OS in BC patients.   In the context of BC, HOXA5 has been shown 
to have a growth suppressive effect by promoting apoptosis in a p53-dependant or 
independent manner.  Raman and colleagues showed that HOXA5 interacts with the p53 
promoter to activate it expression and thus induce p53-mediated apoptosis in MCF-7 ER+ 
BC cells (261).   Additionally, HOXA5 was shown to bind with TWIST (a negative regulator 
of p53), thereby reducing its suppressive effect on p53 in BC cells (271). Alternatively, 
HOXA5 was also shown to induce apoptosis in a p53-independent independent way via 
caspases 2 and 8 (260).  
Other studies have also shown that HOXA5 is involved in retinoic acid (RA) induced 
apoptosis in BC cells, where RA was shown to induce HOXA5 expression to mediate its 
growth suppressive effects.  Furthermore, a follow up study revealed a post-
transcriptional modulation of RA-induced HOXA5 expression, where miR-130a and the 
RNA binding protein-human antigen R were found to be involved in HOXA5 upregulation 
following RA treatment (295).   
 
Furthermore, Teo and colleagues defined the role of HOXA5 in maintaining certain 
molecular features such as cell-cell adhesion and markers of differentiation in mammary 
epithelial cells.  In their study, reduced HOXA5 expression was shown to increases the 
self-renewal capacity and the acquisition of a more aggressive phenotype in mammary 
epithelial cells, via a reduction in E-cadherin and CD24 levels, whereas HOXA5 
overexpression promoted the differentiation of the progenitor population to a more 
differentiated state (296).   
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Utilizing our miRNA target prediction strategy, we identified HOXA5 as a target for miR-
484, and demonstrated that miR-484 directly binds to the HOXA5 3’-UTR to negatively 
regulate its expression.  Furthermore, we showed that miR-484 is inversely correlated 
with HOXA5 expression in BC patients and cell lines, suggesting that high expression of 
miR-484 in BC patients, particularly in TNBC patients, may be one of the major causes 
that contribute to the suppression of HOXA5 tumor suppressor gene.  In agreement with 
previously published data (260, 261), we found that HOXA5 over expression promoted 
cell death through apoptosis, which was associated with an increase in the active forms 
of caspase-2 and capsase-8.  Furthermore, the growth inhibiting effects of HOXA5 were 
reversed with ectopic overexpression of miR-484 in TNBC cells.  Moreover, we also 
showed that HOXA5 overexpression recapitulated the effects of miR-484 inhibition on cell 
cycle progression, whereby we observed the inhibition of  cell cycle proteins including 
cyclin D1, cyclin E1, as well as CDK4 which is being targeted by novel inhibitors in the 
clinical trials (297).  Since p53 is mutated in almost 80% of TNBC patients (298)  and the 
TNBC cell lines used in our study (MDA-MB-231, MDA-MB-436, and BT-20) harbor p53 
mutations (299), it is possible that HOX5 mediated effects may mostly be mediated 
through p53 independent mechanisms. 
 
Aberrant HOXA5 and miR-484 levels were also reported in other cancer types besides 
BC, suggesting the existence of a possible regulatory pathway in other tumors.  For 
instance, HOXA5 expression levels were found to be reduced in non-small cell lung 
cancer (NSCLC) patients, where HOXA5 was shown to induce cell proliferation by 
upregulating Cdkn1a, encoding the cyclin-dependent kinase inhibitor p21 (300-302).  
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Interestingly, miR-484 was shown to promote NSCLC oncogenesis through inhibiting 
apoptotic protease activating factor (Apaf-1) associated with the suppression of apoptosis 
(303).  However, whether miR-484 function in NSCLC is also via targeting HOXA5 levels 
would be a point of further investigation.   
 
miR-484 was also reported to be highly expressed in serum of colorectal cancer (CRC) 
patients, with its highest expression in the later stages (III-IV) (279, 304), suggesting that 
it may function as an oncogenic miRNA in CRC.  On the contrary, HOXA5 levels were 
shown to be downregulated in CRC tumors, which was associated with upregulation of 
the Wnt/β-catenin pathway.  Moreover, HOXA5 overexpression in CRC lead to reduction 
of their self-renewal capacity via inhibition of Wnt signaling, along with reduction in tumor 
size and metastasis (305).   
 
HOXA5 expression was also found to be lost in angiogenic endothelial cells of the tumor 
vasculature, suggesting the role of HOXA5 in suppressing tumor angiogenesis.  Previous 
studies reported that HOXA5 overexpression was found to inhibit the expression of pro-
angiogenic factors such as VEGFR2, while inducing the anti-angiogenic factor 
Thrombospondin-2 (TSP-2) (306).  Additionally, restoring the expression of HOXA5 also 
inhibited angiogenesis in brain hemangiomas in mice, which was associated with 
increased TSP-2 and reduced hypoxia inducible factor 1 (HIF-1α) expression levels (307).  
In our study, our RPPA analysis revealed that miR-484 induces HIF-1α expression in 
TNBC, one of the major drivers of oncogenesis.  Additionally, we found that in vivo 
inhibition of miR-484 reduced angiogenesis in TNBC tumor xenografts, which was 
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associated with an increase in HOXA5 expression levels.  Collectively, these data 
suggest that miR-484 may promote angiogenesis in TNBC, and the possible existence of 
a regulatory pathway between miR-484 and HOXA5/HIF-1α in modulating angiogenesis 
in TNBC, could be a point of further exploration. 
 
miR-484 as a Novel Molecular Target in TNBC 
Since numerous studies have demonstrated that miRNAs are aberrantly expressed in 
many cancers, and have the ability to regulate multiple cancer-related genes and 
pathways simultaneously, the use of miRNA based therapies represents a promising 
therapeutic approach against cancer (308).  Indeed several miRNAs are currently in 
clinical development or are being evaluated in clinical trials as a therapeutic modality 
against cancer (203).  
One of the key findings in our study is that in vivo therapeutic targeting of miR-484 by 
systemically injected anti-miR-484 nanoparticles significantly inhibits tumor growth in 
TNBC tumor models, with no sign of toxicity during 4 weeks of treatment.  Considering 
the clinical significance and broad expression of miR-484 in TNBC cell lines and BC 
patients (non-TNBC and TNBC tumors), miR-484 represents an excellent molecular 
target in BC especially in the TNBC subtype. 
A major obstacle in the field of miRNA-based cancer therapy is developing a safe and 
effective systemic delivery of therapeutic miRNAs in vivo.  Some obstacles that hinder 
successful miRNA delivery in vivo include degradation by enzymatic nucleases, as well 
as poor cellular uptake, and poor stability (309). 
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Thus, the ideal delivery system for miRNAs or miRNA antagomirs should provide 
sufficient target binding that is tumor tissue specific, and be packaged in a carrier that is 
biodegradable and non-immunogenic (225).  One such strategy that has been extensively 
investigated in the field of RNA interference is the use of nanocarriers.  Nanoparticles are 
submicron in size, usually made up of natural or synthetic lipids or polymers, that can be 
utilized to deliver various cargos such as drugs and oligonucleotides in vivo (230).  
Nanoparticles also offer the advantage that they can be coated with high-affinity ligands 
for tumor-specific receptors to achieve controlled and/or sustained delivery (308). 
Liposomal nanoparticles are among the favorable options for systemic miRNA delivery in 
vivo. (230).  Advantages of these nanoliposomes include their biocompatible and 
biodegradable characteristics, and lack of any apparent toxicity (230).  Several studies 
have shown that incorporation of miRNA mimics/inhibitors in neutral nanoliposomes 
achieved significant reduction in tumor volume and altered the expression of target genes 
in many cancer models including subcutaneous xenografts and orthotopic tumor models 
(161, 237, 310).   Moreover, neutral nanoliposomes did not cause any detectable distress 
or toxicity and were found to be safe in mice (161).   
In our study, we provide the first evidence that in vivo therapeutic targeting of miR-484 by 
nanoliposomes made of DMPC successfully delivered anti-sense miR-484 and reduced 
miR-484 expression in orthotopic TNBC mouse models as detected by qRT-PCR.  
Furthermore, mice treated with miR-484 inhibitor showed an increased expression of 
HOXA5, as well as reduced intra-tumoral proliferation and angiogenesis, and induction of 
apoptosis.  Additionally, we observed a significant inhibition in tumor growth in the miR-
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484 targeted group compared to controls, with no observed side effects, suggesting that 
miR-484 could be a potential therapeutic target in TNBC.  Mechanistically, given the 
previously described role of HOXA5 in inducing apoptosis in BC cells in vitro (260, 261), 
as well as it anti-angiogenic effect on endothelial cells (306, 311), the observed miR-484 
effects in vivo may be in part via induction of HOXA5 expression. 
 
In conclusion, our study provides new insight into the role and mechanism of action of 
miR-484 in TNBC as a potential molecular target, which can further be utilized to develop 
safe and effective miRNA-based therapies for TNBC patients with limited therapeutic 
options.  Collectively, our in vitro and in vivo data, as well as the protein array results 
suggest that miR-484 promotes tumor growth, invasion, metastasis, and progression in 
TNBC cells by regulating multiple oncogenic pathways.  The key findings for our three 
specific aims are summarized in Figure 43.  Thus, our data suggest that miR-484 may 
function as an “onco-miR” in TNBC and may therefore serve a potential therapeutic target.   
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Figure 43: Summary of the key findings depicting the role and mechanism of action 
of miR-484 in TNBC.
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Evaluating the role of miR-484 and HOXA5 in other breast cancer subtypes: 
One of the critical findings in our study is that miR-484 is significantly associated with 
poor OS in BC patients.  According to our TCGA analysis we also found that miR-484 is 
upregulated in all BC subtypes compared to matched normal tissues, with the highest 
expression in the TNBC subtype.  Furthermore, we showed that HOXA5 and miR-484 
expression levels are inversely correlated in BC patients and cell lines, suggesting that 
miR-484 may also promote tumor growth and progression in other BC subtypes by 
targeting HOXA5.  Therefore, further evaluation of role of  miR-484 in other BC tumors 
and whether it functions by targeting HOXA5 may be investigated. 
 
Determining the mechanism of aberrant miR-484 expression in Breast Cancer: 
Aberrant miRNA expression could be due to genetic, epigenetic factors, or factors that 
affect miRNA biogenesis/processing (312).  However, the causes for dysregulation of 
miR-484 expression in TNBC are currently not known.  miRNA transcription can be 
activated by transcription factors that bind to its promoter region.  In search for possible 
transcription factors on the miR-484 promoter region (biobase.mdanderson.edu), we 
found that Nuclear Factor Kappa-B (NF-kB) (Rel A p65 subunit) has multiple predicted 
binding sites on the miR-484 promoter region (data not shown).   NF-kB is a transcription 
factor that is involved in almost all aspects of human cancer (313, 314), and represents 
a key regulator of TNBC (315, 316).  Moreover, NF-kB has been implicated in the 
dysregulated expression of many miRNAs (317).  Thus, further confirmation by CHIP 
assay of whether NF-kB directly binds to the miR-484 promoter to regulate its expression 
could be investigated.  
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Further confirmation that miR-484 mediated events in TNBC are through down 
regulation of HOXA5: 
In this study we showed that inhibition of miR-484 in TNBC cells significantly reduced cell 
proliferation, motility/invasion, and induced cell cycle arrest and apoptosis.  On the other 
hand, miR-484 overexpression resulted in increased cell proliferation, survival, motility 
and invasion, suggesting that it functions as an oncogenic miRNA in TNBC.  Furthermore, 
we identified HOXA5 as a direct target of miR-484 and found that miR-484 directly binds 
to the 3’-UTR of HOXA5 to negatively regulate its expression.   Additionally, HOXA5 over-
expression recapitulated the effects of miR-484 inhibition on apoptosis induction, while 
miR-484 overexpression reversed this effect, suggesting that miR-484 mediates its 
effects through HOXA5 suppression.  However, further examination of whether miR-484 
effects on cell proliferation, motility, and invasion are through HOXA5 downregulation 
should be considered.  Thus, determining whether siRNA mediated knockdown of HOXA5 
can recapitulate miR-484 effects in TNBC could be examined. 
Analysis for in vivo toxicity of Anti-miR-484 treatment in TNBC mouse models: 
In our study, no significant changes in mouse body weights, nor changes in behavioral or 
eating habits were detected during the 4 weeks of the treatment of mice, suggesting that 
anti-miR-484 therapy exerted no or limited side effects.  However, further confirmation by 
clinical biochemistry analyses for mice treated with either miR-484 inhibitor or control 
inhibitor nanoliposomes should be compared.  This can include biochemical parameters 
for kidney, liver, and blood toxicity such as, blood urea nitrogen, glucose, aspartate 
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aminotransferase, alanine aminotransferase, creatinine, total bilirubin, and lactic 
dehydrogenase. 
Further confirmation of miR-484 oncogenic effects in TNBC mouse models:    
We showed that treatment with miR-484 inhibitor reduced tumor growth, proliferation, and 
angiogenesis, and induced apoptosis in TNBC mouse models.  Moreover, we observed 
that these effects were associated with increased HOXA5 expression levels.  However, 
further confirmation of the oncogenic effects of miR-484 can be explored by injecting mice 
with miR-484 mimic to determine its effects on proliferation, angiogenesis, and apoptosis 
would be warranted.  Additionally, tumor samples from mice treated with either miR-484 
inhibitor or mimic can be evaluated for the proliferation, angiogenesis, and apoptosis 
markers by western blot. 
Determining the effect of miR-484 inhibition in combination with standard 
chemotherapy in TNBC: 
According to our in vitro and in vivo results, miR-484 promotes tumor growth and 
progression in TNBC and therefore represents a potentially novel therapeutic target. 
However, further evaluation of combining miR-484 inhibitors with standard 
chemotherapeutics could be evaluated in order to determine a possible synergistic effect 
and maximize treatment efficacy.  Our preliminary experiments have shown that 
combination of miR-484 inhibitor with standard chemotherapeutics such as paclitaxel or 
doxorubicin significantly reduced TNBC cell proliferation than either mono therapies (data 
not shown).  Therefore, further investigation of whether miR-484 increases doxorubicin 
or paclitaxel sensitivity in TNBC cells may be explored.
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Table 3: Antibodies used in Western Blot analysis 
Target Protein Source 
Catalog 
Number 
Application 
GAPDH Cell Signaling Technology 5174 WB, IHC, IF 
HOXA5 Santa Cruz 365784 WB, IP, IF 
Caspase-2 Cell Signaling Technology 2224 WB 
Caspase-8 Cell Signaling Technology 9746 WB, IP 
Cleaved 
Caspase-8 
Cell Signaling Technology 9496 WB, IHC, IF 
Caspase-3 Cell Signaling Technology 9662 WB, IHC, IP 
PARP Cell Signaling Technology 9532 WB, IP, IF 
p-FAK (pY397) B&D Biosciences 611722 WB 
FAK B&D Biosciences 610087 WB 
p-SRC (Tyr416) Cell Signaling Technology 2101 WB 
SRC Cell Signaling Technology 2109 WB, IHC, IF, IP 
CDK2 Cell Signaling Technology 2546 WB, IP 
CDK4 Cell Signaling Technology 12790 WB, IHC, IF 
CDK6 Cell Signaling Technology 13331 WB, IP 
Cyclin D1 Cell Signaling Technology 2978 WB, IHC 
Cyclin E1 Cell Signaling Technology 20808 WB 
p21 Cell Signaling Technology 2947 WB, IHC, IP, IF 
p27 Cell Signaling Technology 3686 WB, IP, IF 
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Table 4: Oligonucleotide sequences for quantitative reverse transcription 
polymerase chain reaction 
Target 
Gene 
Forward Sequence Reverse Sequence 
HOXA5 5’-AGTCATGACAACATAGGCGGC-3’ 
5’-CGGGTCAGGTAACGGTTGAA-
3’ 
GAPDH 5’-CAAGGTCATCCATGACAACTTTG- 3’ 
5’-GTCCACCACCCTGTTGCTGTA 
G-3’ 
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Table 5: Experimentally verified targets for miR-484 by miRWalk2.0  
 
RefseqID Gene 
NM_000702 ATP1A2 
NM_152272 CHMP7 
NM_020699 GATAD2B 
NM_005523 HOXA11 
NM_019102 HOXA5 
NM_001004317 LIN28B 
NM_000254 MTR 
NM_003204 NFE2L1 
NM_002616 PER1 
NM_024297 PHF23 
NM_138300 PYGO2 
NM_031459 SESN2 
NM_144582 TEX261 
NM_013390 TMEM2 
NM_005781 TNK2 
NM_017590 ZC3H7B 
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